17. Literaturverzeichnis – Ösophaguskarzinom
1. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e, V., Krebs in Deutschland für 2015/2016., 2019. 12. Auflage:, https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/fruehere_ausgaben/downloads/krebs_in_deutschland_12.pdf?__blob=publicationFile
2. Kreienberg, R. et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. AWMF-Register-Nummer: 032 - 045OL 2012
3. Beauchamp TL, Childress JF, Priciples of Biomedical Ethics,Oxford University Press 5 th ed 2001
4. (Muster)-Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte (Stand 2011), www.bundesaerztekammer.de (Letzter Aufruf am 10.03.2015)
5. Bundesministerium der Justiz und des Verbraucherschutzes (2013). Gesetz zur Verbesserung der Rechte von Patientinnen und Patienten. Drucksache 7/13. www.bmjv:de/DE/Buerger/gesellschaft/Patientenrechte/node.html (letzter Aufruf am 04.05.2014
6. Lee, C. H., Wu, D. C., Lee, J. M., Wu, I. C., Goan, Y. G., Kao, E. L., et.al. Anatomical subsite discrepancy in relation to the impact of the consumption of alcohol, tobacco and betel quid on esophageal cancer, Int J Cancer, 2007. 120(8): p. 1755-62., https://pubmed.ncbi.nlm.nih.gov/17230518/
7. Pandeya, N., Webb, P. M., Sadeghi, S., Green, A. C., Whiteman, D. C., Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?, Gut, 2010. 59(1): p. 31-8., https://pubmed.ncbi.nlm.nih.gov/19875392/
8. Tramacere, I., La, Vecchia C., Negri, E., Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis, Epidemiology, 2011. 22(3): p. 344-349., https://pubmed.ncbi.nlm.nih.gov/21330928/
9. Rafiq, R., Shah, I. A., Bhat, G. A., Lone, M. M., Islami, F., Boffetta, P., et.al. Secondhand Smoking and the Risk of Esophageal Squamous Cell Carcinoma in a High Incidence Region, Kashmir, India: A Case-control-observational Study, Medicine (Baltimore), 2016. 95(1): p. e2340., https://pubmed.ncbi.nlm.nih.gov/26735535/
10. Sewram, V., Sitas, F., O'Connell, D., Myers, J., Tobacco and alcohol as risk factors for oesophageal cancer in a high incidence area in South Africa, Cancer Epidemiol, 2016. 41: p. 113-21., https://pubmed.ncbi.nlm.nih.gov/26900781/
11. Islami, F., Fedirko, V., Tramacere, I., Bagnardi, V., Jenab, M., Scotti, L., et.al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis, Int J Cancer, 2011. 129(10): p. 2473-2484., https://pubmed.ncbi.nlm.nih.gov/21190191/
12. Bagnardi, V, Rota, M, Botteri, E, Tramacere, I, Islami, F, Fedirko, V, et.al. Light alcohol drinking and cancer: a meta-analysis., Ann Oncol, 2013. 24 (2)(2): p. 301-308., https://pubmed.ncbi.nlm.nih.gov/22910838/
13. Pandeya, N., Williams, G., Green, A. C., Webb, P. M., Whiteman, D. C., Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus, Gastroenterology, 2009. 136(4): p. 1215-24, e1-2., https://pubmed.ncbi.nlm.nih.gov/19250648/
14. Freedman, N. D., Murray, L. J., Kamangar, F., Abnet, C. C., Cook, M. B., Nyren, O., et.al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium, Gut, 2011. 60(8): p. 1029-37., https://pubmed.ncbi.nlm.nih.gov/21406386/
15. Tramacere, I., Pelucchi, C., Bagnardi, V., Rota, M., Scotti, L., Islami, F., et.al. A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk, Ann.Oncol., 2012. 23(2): p. 287-297., https://pubmed.ncbi.nlm.nih.gov/21551004/
16. Nucci, D, Marino, A, Realdon, S, Nardi, M, Fatigoni, C, Gianfredi, V, Lifestyle, WCRF/AICR Recommendations, and Esophageal Adenocarcinoma Risk: A Systematic Review of the Literature., Nutrients, 2021. 13 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/34684526/
17. Ji, J., Sundquist, J., Sundquist, K., Associations of alcohol use disorders with esophageal and gastric cancers: a population-based study in Sweden, Eur J Cancer Prev, 2017. 26(2): p. 119-124., https://pubmed.ncbi.nlm.nih.gov/26886238/
18. Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., Anis, A. H., The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis, BMC.Public Health, 2009. 9: p. 88., https://pubmed.ncbi.nlm.nih.gov/19320986/
19. Ryan, A. M., Duong, M., Healy, L., Ryan, S. A., Parekh, N., Reynolds, J. V., et.al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets, Cancer Epidemiol., 2011. 35(4): p. 309-319., https://pubmed.ncbi.nlm.nih.gov/21470937/
20. Turati, F., Tramacere, I., La Vecchia, C., Negri, E., A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma, Ann Oncol, 2013. 24(3): p. 609-17., https://pubmed.ncbi.nlm.nih.gov/22898040/
21. O'Doherty, M. G., Freedman, N. D., Hollenbeck, A. R., Schatzkin, A., Abnet, C. C., A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study, Gut, 2012. 61(9): p. 1261-8., https://pubmed.ncbi.nlm.nih.gov/22174193/
22. Huang, Y, Cao, D, Chen, Z, Chen, B, Li, J, Wang, R, et.al. Iron intake and multiple health outcomes: Umbrella review., Crit Rev Food Sci Nutr, 2021. (): p. 1-18., https://pubmed.ncbi.nlm.nih.gov/34583608/
23. Xuan, F, Li, W, Guo, X, Liu, C, Dietary carbohydrate intake and the risk of esophageal cancer: a meta-analysis., Biosci Rep, 2020. 40 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/32027364/
24. Thota, P. N., Arora, Z., Benjamin, T., Pagadala, M., Lopez, R., Sanaka, M. R., Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.), Scand J Gastroenterol, 2016. 51(11): p. 1288-93., https://pubmed.ncbi.nlm.nih.gov/27460942/
25. Krishnamoorthi, R., Borah, B., Heien, H., Das, A., Chak, A., Iyer, P. G., Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort, Gastrointest Endosc, 2016. 84(1): p. 40-46.e7., https://pubmed.ncbi.nlm.nih.gov/26772891/
26. Ji, J., Hemminki, K., Familial risk for esophageal cancer: an updated epidemiologic study from Sweden, Clin Gastroenterol Hepatol, 2006. 4(7): p. 840-5., https://pubmed.ncbi.nlm.nih.gov/16678496/
27. Leeuwenburgh, I., Scholten, P., Alderliesten, J., Tilanus, H. W., Looman, C. W., Steijerberg, E. W., et.al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study, Am J Gastroenterol, 2010. 105(10): p. 2144-9., https://pubmed.ncbi.nlm.nih.gov/20588263/
28. Zendehdel, K., Nyren, O., Edberg, A., Ye, W., Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden, Am J Gastroenterol, 2011. 106(1): p. 57-61., https://pubmed.ncbi.nlm.nih.gov/21212754/
29. Taylor, C, Correa, C, Duane, FK, Aznar, MC, Anderson, SJ, Bergh, J, et.al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials., J Clin Oncol, 2017. 35 (15)(15): p. 1641-1649., https://pubmed.ncbi.nlm.nih.gov/28319436/
30. Berrington de Gonzalez, A, Curtis, RE, Kry, SF, Gilbert, E, Lamart, S, Berg, CD, et.al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries., Lancet Oncol, 2011. 12 (4)(4): p. 353-60., https://pubmed.ncbi.nlm.nih.gov/21454129/
31. Han, C, Wu, Y, Kang, K, Wang, Z, Liu, Z, Zhang, F, Long-term radiation therapy-related risk of second primary malignancies in patients with lung cancer., J Thorac Dis, 2021. 13 (10)(10): p. 5863-5874., https://pubmed.ncbi.nlm.nih.gov/34795935/
32. Morton, L. M., Gilbert, E. S., Hall, P., Andersson, M., Joensuu, H., Vaalavirta, L., et.al. Risk of treatment-related esophageal cancer among breast cancer survivors, Ann Oncol, 2012. 23(12): p. 3081-91., https://pubmed.ncbi.nlm.nih.gov/22745217/
33. Morton, LM, Gilbert, ES, Stovall, M, van Leeuwen, FE, Dores, GM, Lynch, CF, et.al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma., Haematologica, 2014. 99 (10)(10): p. e193-6., https://pubmed.ncbi.nlm.nih.gov/25271315/
34. Zablotska, L. B., Chak, A., Das, A., Neugut, A. I., Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer, Am J Epidemiol, 2005. 161(4): p. 330-7., https://pubmed.ncbi.nlm.nih.gov/15692076/
35. Roychoudhuri, R., Evans, H., Robinson, D., Moller, H., Radiation-induced malignancies following radiotherapy for breast cancer, Br J Cancer, 2004. 91(5): p. 868-72., https://pubmed.ncbi.nlm.nih.gov/15292931/
36. Okonta, K. E., Tettey, M., Abubakar, U., In patients with corrosive oesophageal stricture for surgery, is oesophagectomy rather than bypass necessary to reduce the risk of oesophageal malignancy?, Interact Cardiovasc Thorac Surg, 2012. 15(4): p. 713-5., https://pubmed.ncbi.nlm.nih.gov/22821650/
37. Lagergren, J., Bergstrom, R., Lindgren, A., Nyren, O., Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma, N Engl J Med, 1999. 340(11): p. 825-31., https://pubmed.ncbi.nlm.nih.gov/10080844/
38. Velanovich, V., Hollingsworth, J., Suresh, P., Ben-Menachem, T., Relationship of gastroesophageal reflux disease with adenocarcinoma of the distal esophagus and cardia, Dig Surg, 2002. 19(5): p. 349-53., https://pubmed.ncbi.nlm.nih.gov/12435904/
39. Wu, A. H., Tseng, C. C., Bernstein, L., Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma, Cancer, 2003. 98(5): p. 940-8., https://pubmed.ncbi.nlm.nih.gov/12942560/
40. Chak, A., Faulx, A., Eng, C., Grady, W., Kinnard, M., Ochs-Balcom, H., et.al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia, Cancer, 2006. 107(9): p. 2160-6., https://pubmed.ncbi.nlm.nih.gov/17019737/
41. Rubenstein, J. H., Taylor, J. B., Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux, Aliment.Pharmacol.Ther., 2010. 32(10): p. 1222-1227., https://pubmed.ncbi.nlm.nih.gov/20955441/
42. Hazelton, W. D., Curtius, K., Inadomi, J. M., Vaughan, T. L., Meza, R., Rubenstein, J. H., et.al. The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma, Cancer Epidemiol Biomarkers Prev, 2015. 24(7): p. 1012-23., https://pubmed.ncbi.nlm.nih.gov/25931440/
43. Anaparthy, R., Gaddam, S., Kanakadandi, V., Alsop, B. R., Gupta, N., Higbee, A. D., et.al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia, Clin Gastroenterol Hepatol, 2013. 11(11): p. 1430-6., https://pubmed.ncbi.nlm.nih.gov/23707463/
44. Desai, T. K., Krishnan, K., Samala, N., Singh, J., Cluley, J., Perla, S., et.al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis, Gut, 2012. 61(7): p. 970-976., https://pubmed.ncbi.nlm.nih.gov/21997553/
45. Gaddam, S., Singh, M., Balasubramanian, G., Thota, P., Gupta, N., Wani, S., et.al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort, Gastroenterology, 2013. 145(3): p. 548-53.e1., https://pubmed.ncbi.nlm.nih.gov/23714382/
46. Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sorensen, H. T., Funch-Jensen, P., Incidence of adenocarcinoma among patients with Barrett's esophagus, N Engl J Med, 2011. 365(15): p. 1375-83., https://pubmed.ncbi.nlm.nih.gov/21995385/
47. Koop, H., Fuchs, K. H., Labenz, J., Lynen Jansen, P., Messmann, H., Miehlke, S., et.al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013, Z Gastroenterol, 2014. 52(11): p. 1299-346., https://pubmed.ncbi.nlm.nih.gov/25390216/
48. Solaymani-Dodaran, M., Card, T. R., West, J., Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study, Gastroenterology, 2013. 144(7): p. 1375-83, 1383.e1., https://pubmed.ncbi.nlm.nih.gov/23583429/
49. Wani, S., Falk, G., Hall, M., Gaddam, S., Wang, A., Gupta, N., et.al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma, Clin Gastroenterol Hepatol, 2011. 9(3): p. 220-7; quiz e26., https://pubmed.ncbi.nlm.nih.gov/21115133/
50. Cooper, S., Menon, S., Nightingale, P., Trudgill, Nj, Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study, United European Gastroenterol J, 2014. 2(2): p. 91-8., https://pubmed.ncbi.nlm.nih.gov/24918013/
51. Nguyen, T., Thrift, A. P., Yu, X., Duan, Z., El-Serag, H. B., The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus, Am J Gastroenterol, 2017. 112(7): p. 1049-1055., https://pubmed.ncbi.nlm.nih.gov/28244499/
52. Masclee, G. M., Coloma, P. M., de Wilde, M., Kuipers, E. J., Sturkenboom, M. C., The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off, Aliment Pharmacol Ther, 2014. 39(11): p. 1321-30., https://pubmed.ncbi.nlm.nih.gov/24738722/
53. Kestens, C., Offerhaus, G. J., van Baal, J. W., Siersema, P. D., Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer, Clin Gastroenterol Hepatol, 2016. 14(7): p. 956-962.e1., https://pubmed.ncbi.nlm.nih.gov/26748222/
54. Steinberg, J., Schwertner, C., de Villiers, E. M., Mir-Salim, P., Kiesslich, R., Stoelzel, U., et.al. Koinzidenz von Plattenepithelkarzinomen der Speiseröhre und Kopf-Hals-Karzinomen: Risiko und Früherkennung, TumorDiagn u Ther, 2008. 29(01): p. 35-39., https://pubmed.ncbi.nlm.nih.gov/17701861/
55. Moschler, O., Spahn, T. W., Middelberg-Bisping, C., Grosse-Thie, W., Christoph, B., Kloeppel, G., et.al. Chromoendoscopy is a valuable tool for screening of high-risk patients with head and neck cancer for early detection of esophageal cancer, Digestion, 2006. 73(2-3): p. 160-6., https://pubmed.ncbi.nlm.nih.gov/16837800/
56. Ljung, R., Martin, L., Lagergren, J., Oral disease and risk of oesophageal and gastric cancer in a nationwide nested case-control study in Sweden, Eur J Cancer, 2011. 47(14): p. 2128-32., https://pubmed.ncbi.nlm.nih.gov/21489778/
57. Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., Guidelines for the management of oesophageal and gastric cancer, Gut, 2011. 60(11): p. 1449-1472., https://pubmed.ncbi.nlm.nih.gov/21705456/
58. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., Meade, T. W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, Lancet, 2011. 377(9759): p. 31-41., https://pubmed.ncbi.nlm.nih.gov/21144578/
59. Algra, A. M., Rothwell, P. M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol., 2012. 13(5): p. 518-527., https://pubmed.ncbi.nlm.nih.gov/22440112/
60. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V. und Deutschen Krebshilfe, S3-Leitlinie Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs, Langversion 2.0, AWMF-Registernummer: 032/009OL, 2019., https://www.leitlinienprogramm-onkologie.de/leitlinien/magenkarzinom/
61. Cook, N. R., Lee, I. M., Zhang, S. M., Moorthy, M. V., Buring, J. E., Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial, Ann Intern Med, 2013. 159(2): p. 77-85., https://pubmed.ncbi.nlm.nih.gov/23856681/
62. Cardwell, C. R., Abnet, C. C., Veal, P., Hughes, C. M., Cantwell, M. M., Murray, L. J., Exposure to oral bisphosphonates and risk of cancer, Int J Cancer, 2012. 131(5): p. E717-25., https://pubmed.ncbi.nlm.nih.gov/22161552/
63. Green, J., Czanner, G., Reeves, G., Watson, J., Wise, L., Beral, V., Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort, BMJ, 2010. 341: p. c4444., https://pubmed.ncbi.nlm.nih.gov/20813820/
64. Oh, Y. H., Yoon, C., Park, S. M., Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies, World J Gastroenterol., 2012. 18(40): p. 5779-5788., https://pubmed.ncbi.nlm.nih.gov/3484348/
65. Haber, S. L., McNatty, D., An evaluation of the use of oral bisphosphonates and risk of esophageal cancer, Ann.Pharmacother., 2012. 46(3): p. 419-423., https://pubmed.ncbi.nlm.nih.gov/22333262/
66. Andrici, J., Tio, M., Eslick, G. D., Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer, Aliment Pharmacol Ther, 2012. 36(8): p. 708-16., https://pubmed.ncbi.nlm.nih.gov/22966908/
67. Busby, J., Murchie, P., Murray, L., Iversen, L., Lee, A. J., Spence, A., et.al. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data, Int J Cancer, 2017. 140(8): p. 1828-1835., https://pubmed.ncbi.nlm.nih.gov/28120338/
68. Bjelakovic, G., Nikolova, D., Simonetti, R. G., Gluud, C., Antioxidant supplements for preventing gastrointestinal cancers, Cochrane.Database.Syst.Rev., 2008. p. CD004183., https://pubmed.ncbi.nlm.nih.gov/18677777/
69. Vigen, C., Bernstein, L., Wu, A. H., Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach, Int J Cancer, 2006. 118(4): p. 1004-9., https://pubmed.ncbi.nlm.nih.gov/16152595/
70. Stehle, P., Deutsche Gesellschaft für Ernährung. 12. Ernährungsbericht 2012, European Journal of Nutrition an Food Safety, 2012. 4(1): p. 2347-564.
71. Liu, J., Wang, J., Leng, Y., Lv, C., Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies, Int J Cancer, 2013. 133(2): p. 473-85., https://pubmed.ncbi.nlm.nih.gov/23319052/
72. Choi, Y., Song, S., Song, Y., Lee, J. E., Consumption of red and processed meat and esophageal cancer risk: meta-analysis, World J Gastroenterol, 2013. 19(7): p. 1020-9., https://pubmed.ncbi.nlm.nih.gov/23467465/
73. Keszei, A. P., Schouten, L. J., Goldbohm, R. A., van den Brandt, P. A., Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study, Ann Oncol, 2012. 23(9): p. 2319-26., https://pubmed.ncbi.nlm.nih.gov/22351741/
74. Huang, W., Han, Y., Xu, J., Zhu, W., Li, Z., Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies, Cancer Causes Control, 2013. 24(1): p. 193-201., https://pubmed.ncbi.nlm.nih.gov/23179661/
75. Jakszyn, P., Lujan-Barroso, L., Agudo, A., Bueno-de-Mesquita, H. B., Molina, E., Sanchez, M. J., et.al. Meat and heme iron intake and esophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study, Int J Cancer, 2013. 133(11): p. 2744-50., https://pubmed.ncbi.nlm.nih.gov/23728954/
76. Salehi, M., Moradi-Lakeh, M., Salehi, M. H., Nojomi, M., Kolahdooz, F., Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis, Nutr Rev, 2013. 71(5): p. 257-67., https://pubmed.ncbi.nlm.nih.gov/23590703/
77. Palmer, J. B., Drennan, J. C., Baba, M., Evaluation and treatment of swallowing impairments, Am Fam Physician, 2000. 61(8): p. 2453-62., https://pubmed.ncbi.nlm.nih.gov/10794585/
78. Behrens, A., Labenz, J., Schuler, A., Schroder, W., Runzi, M., Steinmann, R. U., et.al. How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from prospective registries of complications managed by members of the Working Group of Leading Hospital Gastroenterologists (ALGK), Z Gastroenterol, 2013. 51(5): p. 432-6., https://pubmed.ncbi.nlm.nih.gov/23681895/
79. Curvers, W. L., Alvarez Herrero, L., Wallace, M. B., Wong Kee Song, L. M., Ragunath, K., Wolfsen, H. C., et.al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus, Gastroenterology, 2010. 139(4): p. 1106-14., https://pubmed.ncbi.nlm.nih.gov/20600033/
80. Hori, K., Okada, H., Kawahara, Y., Takenaka, R., Shimizu, S., Ohno, Y., et.al. Lugol-voiding lesions are an important risk factor for a second primary squamous cell carcinoma in patients with esosphageal cancer or head and neck cancer, Am J Gastroenterol, 2011. 106(5): p. 858-66., https://pubmed.ncbi.nlm.nih.gov/21468010/
81. Qumseya, B. J., Wang, H., Badie, N., Uzomba, R. N., Parasa, S., White, D. L., et.al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review, Clin Gastroenterol Hepatol, 2013. 11(12): p. 1562-70.e1-2., https://pubmed.ncbi.nlm.nih.gov/23851020/
82. Chung, C. S., Lo, W. C., Lee, Y. C., Wu, M. S., Wang, H. P., Liao, L. J., Image-enhanced endoscopy for detection of second primary neoplasm in patients with esophageal and head and neck cancer: A systematic review and meta-analysis, Head Neck, 2016. 38 Suppl 1: p. E2343-9., https://pubmed.ncbi.nlm.nih.gov/26595056/
83. Curvers, W. L., ten Kate, F. J., Krishnadath, K. K., Visser, M., Elzer, B., Baak, L. C., et.al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated, Am J Gastroenterol, 2010. 105(7): p. 1523-30., https://pubmed.ncbi.nlm.nih.gov/20461069/
84. Uedo, N., Fujishiro, M., Goda, K., Hirasawa, D., Kawahara, Y., Lee, J. H., et.al. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region, Dig Endosc, 2011. 23 Suppl 1: p. 58-71., https://pubmed.ncbi.nlm.nih.gov/21535204/
85. Sharma, P., Hawes, R. H., Bansal, A., Gupta, N., Curvers, W., Rastogi, A., et.al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial, Gut, 2013. 62(1): p. 15-21., https://pubmed.ncbi.nlm.nih.gov/22315471/
86. Canto, M. I., Anandasabapathy, S., Brugge, W., Falk, G. W., Dunbar, K. B., Zhang, Z., et.al. In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video), Gastrointest Endosc, 2014. 79(2): p. 211-21., https://pubmed.ncbi.nlm.nih.gov/24219822/
87. Fugazza, A., Gaiani, F., Carra, M. C., Brunetti, F., Levy, M., Sobhani, I., et.al. Confocal Laser Endomicroscopy in Gastrointestinal and Pancreatobiliary Diseases: A Systematic Review and Meta-Analysis, Biomed Res Int, 2016. 2016: p. 4638683., https://pubmed.ncbi.nlm.nih.gov/26989684/
88. Gupta, A., Attar, B. M., Koduru, P., Murali, A. R., Go, B. T., Agarwal, R., Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis, Eur J Gastroenterol Hepatol, 2014. 26(4): p. 369-77., https://pubmed.ncbi.nlm.nih.gov/24535597/
89. Coletta, M., Sami, S. S., Nachiappan, A., Fraquelli, M., Casazza, G., Ragunath, K., Acetic acid chromoendoscopy for the diagnosis of early neoplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis, Gastrointest Endosc, 2016. 83(1): p. 57-67.e1., https://pubmed.ncbi.nlm.nih.gov/26371851/
90. Qumseya, B. J., Wang, H., Badie, N., Uzomba, R. N., Parasa, S., White, D. L., et.al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review, Clin Gastroenterol Hepatol, 2013. 11(12): p. 1562-70.e1-2., https://pubmed.ncbi.nlm.nih.gov/23851020/
91. Lim, H., Kim do, H., Jung, H. Y., Gong, E. J., Na, H. K., Ahn, J. Y., et.al. Clinical significance of early detection of esophageal cancer in patients with head and neck cancer, Gut Liver, 2015. 9(2): p. 159-65., https://pubmed.ncbi.nlm.nih.gov/25167869/
92. Katada, C., Muto, M., Nakayama, M., Tanabe, S., Higuchi, K., Sasaki, T., et.al. Risk of superficial squamous cell carcinoma developing in the head and neck region in patients with esophageal squamous cell carcinoma, Laryngoscope, 2012. 122(6): p. 1291-6., https://pubmed.ncbi.nlm.nih.gov/22674532/
93. Chow, T. L., Lee, D. T., Choi, C. Y., Chan, T. T., Lam, S. H., Prediction of simultaneous esophageal lesions in head and neck squamous cell carcinoma: a multivariate analysis, Arch Otolaryngol Head Neck Surg, 2009. 135(9): p. 882-5., https://pubmed.ncbi.nlm.nih.gov/19770420/
94. Muto, M., Hironaka, S., Nakane, M., Boku, N., Ohtsu, A., Yoshida, S., Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer, Gastrointest Endosc, 2002. 56(4): p. 517-21., https://pubmed.ncbi.nlm.nih.gov/12297767/
95. Gruner, M, Denis, A, Masliah, C, Amil, M, Metivier-Cesbron, E, Luet, D, et.al. Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial., Endoscopy, 2021. 53 (7)(7): p. 674-682., https://pubmed.ncbi.nlm.nih.gov/32698233/
96. Thosani, N, Abu Dayyeh, BK, Sharma, P, Aslanian, HR, Enestvedt, BK, Komanduri, S, et.al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real-time imaging-assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett's esophagus., Gastrointest Endosc, 2016. 83 (4)(4): p. 684-98.e7., https://pubmed.ncbi.nlm.nih.gov/26874597/
97. Ebigbo, A, Mendel, R, Probst, A, Manzeneder, J, Souza, LA, Papa, JP, et.al. Computer-aided diagnosis using deep learning in the evaluation of early oesophageal adenocarcinoma., Gut, 2019. 68 (7)(7): p. 1143-1145., https://pubmed.ncbi.nlm.nih.gov/30510110/
98. Hashimoto, R, Requa, J, Dao, T, Ninh, A, Tran, E, Mai, D, et.al. Artificial intelligence using convolutional neural networks for real-time detection of early esophageal neoplasia in Barrett's esophagus (with video)., Gastrointest Endosc, 2020. 91 (6)(6): p. 1264-1271.e1., https://pubmed.ncbi.nlm.nih.gov/31930967/
99. de Groof, AJ, Struyvenberg, MR, van der Putten, J, van der Sommen, F, Fockens, KN, Curvers, WL, et.al. Deep-Learning System Detects Neoplasia in Patients With Barrett's Esophagus With Higher Accuracy Than Endoscopists in a Multistep Training and Validation Study With Benchmarking., Gastroenterology, 2020. 158 (4)(4): p. 915-929.e4., https://pubmed.ncbi.nlm.nih.gov/31759929/
100. Puli, S. R., Reddy, J. B., Bechtold, M. L., Antillon, D., Ibdah, J. A., Antillon, M. R., Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review, World J Gastroenterol., 2008. 14(10): p. 1479-1490., https://pubmed.ncbi.nlm.nih.gov/18330935/
101. Thosani, N., Singh, H., Kapadia, A., Ochi, N., Lee, J. H., Ajani, J., et.al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis, Gastrointest.Endosc., 2012. 75(2): p. 242-253., https://pubmed.ncbi.nlm.nih.gov/22115605/
102. Tranchemontagne, J., Stadification initiale du cancer de l'oesophage: revue systematique sur la performance des methodes diagnostiques. Initial staging of oesophageal cancer: systematic review of the performance of diagnostic methods, Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). ETMIS 5(6). Montreal 2009
103. van Vliet, E. P., Heijenbrok-Kal, M. H., Hunink, M. G., Kuipers, E. J., Siersema, P. D., Staging investigations for oesophageal cancer: a meta-analysis, Br.J Cancer, 2008. 98(3): p. 547-557., https://pubmed.ncbi.nlm.nih.gov/18212745/
104. Russell, I, Edwards, R, Gliddon, A, Ingledew, D, Russell, D, Whitaker, R, et.al. Cancer of oesophagus or gastricus: New assessment of technology of endosonography (COGNATE): Report of pragmatic randomised trial, Health technology assessment, 2013. 17(39): p. 1-13., https://pubmed.ncbi.nlm.nih.gov/24034150/
105. Luo, L. N., He, L. J., Gao, X. Y., Huang, X. X., Shan, H. B., Luo, G. Y., et.al. Endoscopic Ultrasound for Preoperative Esophageal Squamous Cell Carcinoma: a Meta-Analysis, PLoS One, 2016. 11(7): p. e0158373., https://pubmed.ncbi.nlm.nih.gov/27387830/
106. Takizawa, K., Matsuda, T., Kozu, T., Eguchi, T., Kato, H., Nakanishi, Y., et.al. Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography, J Gastroenterol Hepatol, 2009. 24(10): p. 1687-91., https://pubmed.ncbi.nlm.nih.gov/19788609/
107. Stiles, B. M., Mirza, F., Coppolino, A., Port, J. L., Lee, P. C., Paul, S., et.al. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease, Ann Thorac Surg, 2011. 92(2): p. 491-6; discussion 496-8., https://pubmed.ncbi.nlm.nih.gov/21704291/
108. Qumseya, B. J., Bartel, M. J., Gendy, S., Bain, P., Qumseya, A., Wolfsen, H., High rate of over-staging of Barrett's neoplasia with endoscopic ultrasound: Systemic review and meta-analysis, Dig Liver Dis, 2018. 50(5): p. 438-445., https://www.ncbi.nlm.nih.gov/pubmed/29573963
109. de Gouw, Djjm, Klarenbeek, B. R., Driessen, M., Bouwense, S. A. W., van Workum, F., Futterer, J. J., et.al. Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis, J Thorac Oncol, 2019. 14(7): p. 1156-1171., https://www.ncbi.nlm.nih.gov/pubmed/30999111
110. Eyck, B. M., Onstenk, B. D., Noordman, B. J., Nieboer, D., Spaander, M. C. W., Valkema, R., et.al. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis, Ann Surg, 2020. 271(2): p. 245-256., https://www.ncbi.nlm.nih.gov/pubmed/31188203
111. Noordman, B. J., Spaander, M. C. W., Valkema, R., Wijnhoven, B. P. L., van Berge Henegouwen, M. I., Shapiro, J., et.al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study, Lancet Oncol, 2018. 19(7): p. 965-974., https://www.ncbi.nlm.nih.gov/pubmed/29861116
112. Oldenburg, A., Albrecht, T., Sonografische Leberdiagnostik bei Tumorpatienten ohne und mit Kontrastmittel, Ultraschall in Med, 2008. 29: p. 488-498., https://pubmed.ncbi.nlm.nih.gov/19241505/
113. Kinkel, K., Lu, Y., Both, M., Warren, R. S., Thoeni, R. F., Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis, Radiology, 2002. 224(3): p. 748-56., https://pubmed.ncbi.nlm.nih.gov/12202709/
114. Piscaglia, F., Corradi, F., Mancini, M., Giangregorio, F., Tamberi, S., Ugolini, G., et.al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer, BMC Cancer, 2007. 7: p. 171., https://pubmed.ncbi.nlm.nih.gov/17767722/
115. Dietrich, C. F., Kratzer, W., Strobe, D., Danse, E., Fessl, R., Bunk, A., et.al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI, World J Gastroenterol, 2006. 12(11): p. 1699-705., https://pubmed.ncbi.nlm.nih.gov/16586537/
116. Albrecht, T., Blomley, M. J., Burns, P. N., Wilson, S., Harvey, C. J., Leen, E., et.al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study, Radiology, 2003. 227(2): p. 361-70., https://pubmed.ncbi.nlm.nih.gov/12649417/
117. Hanle, M. M., Thiel, R., Saur, G., Mason, R. A., Pauls, S., Kratzer, W., Screening for liver metastases in women with mammary carcinoma: comparison of contrast-enhanced ultrasound and magnetic resonance imaging, Clin Imaging, 2011. 35(5): p. 366-70., https://pubmed.ncbi.nlm.nih.gov/21872126/
118. Seitz, K., Strobel, D., Bernatik, T., Blank, W., Friedrich-Rust, M., Herbay, Av, et.al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos, Ultraschall Med, 2009. 30(4): p. 383-9., https://pubmed.ncbi.nlm.nih.gov/19688670/
119. Seitz, K., Bernatik, T., Strobel, D., Blank, W., Friedrich-Rust, M., Strunk, H., et.al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients, Ultraschall Med, 2010. 31(5): p. 492-9., https://pubmed.ncbi.nlm.nih.gov/20652854/
120. Strobel, D., Seitz, K., Blank, W., Schuler, A., Dietrich, C. F., von Herbay, A., et.al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS), Ultraschall Med, 2009. 30(4): p. 376-82., https://pubmed.ncbi.nlm.nih.gov/19688669/
121. Westwood, M., Joore, M., Grutters, J., Redekop, K., Armstrong, N., Lee, K., et.al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis, Health Technol Assess, 2013. 17(16): p. 1-243., https://pubmed.ncbi.nlm.nih.gov/23611316/
122. Doldi, S. B., Lattuada, E., Zappa, M. A., Cioffi, U., Pieri, G., Massari, M., et.al. Ultrasonographic evaluation of the cervical lymph nodes in preoperative staging of esophageal neoplasms, Abdom Imaging, 1998. 23(3): p. 275-7., https://pubmed.ncbi.nlm.nih.gov/9569295/
123. Lerut T, Stordeur S, Verleye L,, Vlayen J, Boterberg T, Clinical Practice Guidelines Upper Gastrointestinal Cancer - update, 2012., https://kce.fgov.be/publication/report/update-of-the-national-guideline-on-upper-gastrointestinal-cancer
124. Schreurs, L. M., Verhoef, C. C., van der Jagt, E. J., van Dam, G. M., Groen, H., Plukker, J. T., Current relevance of cervical ultrasonography in staging cancer of the esophagus and gastroesophageal junction, Eur J Radiol, 2008. 67(1): p. 105-11., https://pubmed.ncbi.nlm.nih.gov/17681735/
125. Van Overhagen, H., Lameris, J. S., Berger, M. Y., Tilanus, H. W., Van Pel, R., Klooswijk, A. I., et.al. Improved assessment of supraclavicular and abdominal metastases in oesophageal and gastro-oesophageal junction carcinoma with the combination of ultrasound and computed tomography, Br J Radiol, 1993. 66(783): p. 203-8., https://pubmed.ncbi.nlm.nih.gov/8472112/
126. van Vliet, E. P., Steyerberg, E. W., Eijkemans, M. J., Kuipers, E. J., Siersema, P. D., Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis, Br J Cancer, 2007. 97(7): p. 868-76., https://pubmed.ncbi.nlm.nih.gov/17848957/
127. Omloo, J. M., van Heijl, M., Smits, N. J., Phoa, S. S., van Berge Henegouwen, M. I., Sloof, G. W., et.al. Additional value of external ultrasonography of the neck after CT and PET scanning in the preoperative assessment of patients with esophageal cancer, Dig Surg, 2009. 26(1): p. 43-9., https://pubmed.ncbi.nlm.nih.gov/19155627/
128. van Overhagen, H., Lameris, J. S., Berger, M. Y., van Pel, R., Tilanus, H. W., Klooswijk, A. I., et.al. Assessment of distant metastases with ultrasound-guided fine-needle aspiration biopsy and cytologic study in carcinoma of the esophagus and gastroesophageal junction, Gastrointest Radiol, 1992. 17(4): p. 305-10., https://pubmed.ncbi.nlm.nih.gov/1426845/
129. van Overhagen, H., Lameris, J. S., Berger, M. Y., van der Voorde, F., Tilanus, H. W., Klooswijk, A. I., et.al. Supraclavicular lymph node metastases in carcinoma of the esophagus and gastroesophageal junction: assessment with CT, US, and US-guided fine-needle aspiration biopsy, Radiology, 1991. 179(1): p. 155-8., https://pubmed.ncbi.nlm.nih.gov/2006268/
130. Mori, S., Kasai, M., Watanabe, T., Shibuya, I., Preoperative assessment of resectability for carcinoma of the thoracic esophagus. Part I. Esophagogram and azygogram, Ann Surg, 1979. 190(1): p. 100-5., https://pubmed.ncbi.nlm.nih.gov/464671/
131. Kumbasar, B., Carcinoma of esophagus: radiologic diagnosis and staging, Eur J Radiol, 2002. 42(3): p. 170-80., https://pubmed.ncbi.nlm.nih.gov/12044696/
132. Fiore, D., Baggio, V., Ruol, A., Bocus, P., Casara, D., Corti, L., et.al. Multimodal imaging of esophagus and cardia cancer before and after treatment, Radiol Med, 2006. 111(6): p. 804-17., https://pubmed.ncbi.nlm.nih.gov/16896560/
133. Moreto, M., Diagnosis of esophagogastric tumors, Endoscopy, 2005. 37(1): p. 26-32., https://pubmed.ncbi.nlm.nih.gov/15657854/
134. Kim, T. J., Kim, H. Y., Lee, K. W., Kim, M. S., Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy, Radiographics, 2009. 29(2): p. 403-21., https://pubmed.ncbi.nlm.nih.gov/19325056/
135. Pech, Oliver, May, Andrea, Gunter, Erwin, Gossner, Liebwin, Ell, Christian, The Impact of Endoscopic Ultrasound and Computed Tomography on the TNM Staging of Early Cancer in Barrett's Esophagus, Am J Gastroenterol, 2006. 101(10): p. 2223-2229., https://pubmed.ncbi.nlm.nih.gov/17032186/
136. Quint, L. E., Thoracic complications and emergencies in oncologic patients, Cancer Imaging, 2009. 9 Spec No A: p. S75-82., https://pubmed.ncbi.nlm.nih.gov/19965299/
137. Ba-Ssalamah, A., Matzek, W., Baroud, S., Bastati, N., Zacherl, J., Schoppmann, S. F., et.al. Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results, Eur Radiol, 2011. 21(11): p. 2326-35., https://pubmed.ncbi.nlm.nih.gov/21710266/
138. Choi, J., Kim, S. G., Kim, J. S., Jung, H. C., Song, I. S., Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer, Surg Endosc, 2010. 24(6): p. 1380-6., https://pubmed.ncbi.nlm.nih.gov/20033712/
139. Gollub, M. J., Lefkowitz, R., Moskowitz, C. S., Ilson, D., Kelsen, D., Felderman, H., Pelvic CT in patients with esophageal cancer, AJR Am J Roentgenol, 2005. 184(2): p. 487-90., https://pubmed.ncbi.nlm.nih.gov/15671368/
140. Kamel, I. R., Fishman, E. K., Recent advances in CT imaging of liver metastases, Cancer J, 2004. 10(2): p. 104-20., https://pubmed.ncbi.nlm.nih.gov/15130270/
141. Lowe, V. J., Booya, F., Fletcher, J. G., Nathan, M., Jensen, E., Mullan, B., et.al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer, Mol Imaging Biol, 2005. 7(6): p. 422-30., https://pubmed.ncbi.nlm.nih.gov/16270235/
142. Makarawo, T. P., Negussie, E., Malde, S., Tilak, J., Gayagoy, J., Watson, J., et.al. Water as a contrast medium: a re-evaluation using the multidetector-row computed tomography, Am Surg, 2013. 79(7): p. 728-33., https://pubmed.ncbi.nlm.nih.gov/23816008/
143. Network, Scottish Intercollegiate Guidelines, Scottish Intercollegiate Guidelines Network Management of oesophageal and gastric cancer. A national clinical guideline., 2006., https://archive.org/details/managementofoeso0000scot
144. Heger, U., Blank, S., Wiecha, C., Langer, R., Weichert, W., Lordick, F., et.al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?, Ann Surg Oncol, 2014. 21(5): p. 1739-48., https://pubmed.ncbi.nlm.nih.gov/24419755/
145. Blank, S., Lordick, F., Dobritz, M., Grenacher, L., Burian, M., Langer, R., et.al. A reliable risk score for stage IV esophagogastric cancer, Eur J Surg Oncol, 2013. 39(8): p. 823-30., https://pubmed.ncbi.nlm.nih.gov/23375470/
146. Blank, S., Stange, A., Sisic, L., Roth, W., Grenacher, L., Sterzing, F., et.al. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients, Langenbecks Arch Surg, 2013. 398(2): p. 211-20., https://pubmed.ncbi.nlm.nih.gov/23224565/
147. Blank, S., Blaker, H., Schaible, A., Lordick, F., Grenacher, L., Buechler, M., et.al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients, Langenbecks Arch Surg, 2012. 397(1): p. 45-55., https://pubmed.ncbi.nlm.nih.gov/21598045/
148. Sohn, K. M., Lee, J. M., Lee, S. Y., Ahn, B. Y., Park, S. M., Kim, K. M., Comparing MR imaging and CT in the staging of gastric carcinoma, AJR Am J Roentgenol, 2000. 174(6): p. 1551-7., https://pubmed.ncbi.nlm.nih.gov/10845479/
149. Anzidei, M., Napoli, A., Zaccagna, F., Di Paolo, P., Zini, C., Cavallo Marincola, B., et.al. Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology, Radiol Med, 2009. 114(7): p. 1065-79., https://pubmed.ncbi.nlm.nih.gov/19774440/
150. Lauenstein, T. C., Goehde, S. C., Herborn, C. U., Goyen, M., Oberhoff, C., Debatin, J. F., et.al. Whole-body MR imaging: evaluation of patients for metastases, Radiology, 2004. 233(1): p. 139-48., https://pubmed.ncbi.nlm.nih.gov/15317952/
151. Wong, R., Malthaner, R., Esophageal cancer: a systematic review, Curr Probl Cancer, 2000. 24(6): p. 297-373., https://pubmed.ncbi.nlm.nih.gov/11198836/
152. Weber, M. A., Bender, K., von Gall, C. C., Stange, A., Grunberg, K., Ott, K., et.al. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction, J Gastrointestin Liver Dis, 2013. 22(1): p. 45-52., https://pubmed.ncbi.nlm.nih.gov/23539390/
153. Quint, L. E., Bogot, N. R., Staging esophageal cancer, Cancer Imaging, 2008. 8 Spec No A: p. S33-42., https://pubmed.ncbi.nlm.nih.gov/18852079/
154. 1591-223X, Dossier 209-2011 ISSN, Servizio Santario Regionale ER. Dossier 209-2011 ISSN 1591-223X, 2011.
155. Barber, T. W., Duong, C. P., Leong, T., Bressel, M., Drummond, E. G., Hicks, R. J., 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data, J Nucl Med, 2012. 53(6): p. 864-71., https://pubmed.ncbi.nlm.nih.gov/22582047/
156. Cervino, A. R., Evangelista, L., Alfieri, R., Castoro, C., Sileni, V. C., Pomerri, F., et.al. Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?, J Cancer Res Ther, 2012. 8(4): p. 619-25., https://pubmed.ncbi.nlm.nih.gov/23361284/
157. Choi, J. Y., Lee, K. H., Shim, Y. M., Lee, K. S., Kim, J. J., Kim, S. E., et.al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET, J Nucl Med, 2000. 41(5): p. 808-15., https://pubmed.ncbi.nlm.nih.gov/10809196/
158. Downey, R. J., Akhurst, T., Ilson, D., Ginsberg, R., Bains, M. S., Gonen, M., et.al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial, J Clin Oncol, 2003. 21(3): p. 428-32., https://pubmed.ncbi.nlm.nih.gov/12560430/
159. Flamen, P., Lerut, A., Van Cutsem, E., De Wever, W., Peeters, M., Stroobants, S., et.al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma, J Clin Oncol, 2000. 18(18): p. 3202-10., https://pubmed.ncbi.nlm.nih.gov/10986052/
160. Heeren, P. A., Jager, P. L., Bongaerts, F., van Dullemen, H., Sluiter, W., Plukker, J. T., Detection of distant metastases in esophageal cancer with (18)F-FDG PET, J Nucl Med, 2004. 45(6): p. 980-7., https://pubmed.ncbi.nlm.nih.gov/15181133/
161. Hsu, W. H., Hsu, P. K., Wang, S. J., Lin, K. H., Huang, C. S., Hsieh, C. C., et.al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma, Ann Thorac Surg, 2009. 87(5): p. 1564-8., https://pubmed.ncbi.nlm.nih.gov/19379906/
162. Kato, H., Nakajima, M., The efficacy of FDG-PET for the management of esophageal cancer: review article, Ann Thorac Cardiovasc Surg, 2012. 18(5): p. 412-9., https://pubmed.ncbi.nlm.nih.gov/22785452/
163. Noble, F., Bailey, D., Tung, K., Byrne, J. P., Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study, Clin Radiol, 2009. 64(7): p. 699-705., https://pubmed.ncbi.nlm.nih.gov/19520214/
164. Varghese, T. K., Jr., Hofstetter, W. L., Rizk, N. P., Low, D. E., Darling, G. E., Watson, T. J., et.al. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer, Ann Thorac Surg, 2013. 96(1): p. 346-56., https://pubmed.ncbi.nlm.nih.gov/23752201/
165. Medical Services Advisory Committee, 2008., Positron emission tomography for oesophageal and gastric cancer : assessment report / prepared by the Medical Services Advisory Committee with the assistance of Silke Walleser et al. Australia., 2008.
166. Findlay, J. M., Bradley, K. M., Maile, E. J., Braden, B., Maw, J., Phillips-Hughes, J., et.al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy, Br J Surg, 2015. 102(12): p. 1488-99., https://pubmed.ncbi.nlm.nih.gov/26458070/
167. Hu, J., Zhu, D., Yang, Y., Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis, Medicine (Baltimore), 2018. 97(50): p. e13722., https://www.ncbi.nlm.nih.gov/pubmed/30558091
168. Jiang, C., Chen, Y., Zhu, Y., Xu, Y., Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma, J Thorac Dis, 2018. 10(11): p. 6066-6076., https://www.ncbi.nlm.nih.gov/pubmed/30622778
169. IQWIG, Abschlussbericht Nr.172 zur "Positronen-Emissionstomographie (PET) und (PET/CT) bei Ösophaguskarzinom, 2013.
170. CMS final decision on PET in solid tumors, J Nucl Med, 2013. 54(8): p. 11n.
171. Baisi, A., Bonavina, L., Peracchia, A., Bronchoscopic staging of squamous cell carcinoma of the upper thoracic esophagus, Arch Surg, 1999. 134(2): p. 140-3., https://pubmed.ncbi.nlm.nih.gov/10025451/
172. Omloo, J. M., van Heijl, M., Bergman, J. J., Koolen, M. G., van Berge Henegouwen, M. I., van Lanschot, J. J., Value of bronchoscopy after EUS in the preoperative assessment of patients with esophageal cancer at or above the carina, J Gastrointest Surg, 2008. 12(11): p. 1874-9., https://pubmed.ncbi.nlm.nih.gov/18528732/
173. Riedel, M., Hauck, R. W., Stein, H. J., Mounyam, L., Schulz, C., Schomig, A., et.al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study, Chest, 1998. 113(3): p. 687-95., https://pubmed.ncbi.nlm.nih.gov/9515844/
174. Wakamatsu, T., Tsushima, K., Yasuo, M., Yamazaki, Y., Yoshikawa, S., Koide, N., et.al. Usefulness of preoperative endobronchial ultrasound for airway invasion around the trachea: esophageal cancer and thyroid cancer, Respiration, 2006. 73(5): p. 651-7., https://pubmed.ncbi.nlm.nih.gov/16675895/
175. Osugi, H., Nishimura, Y., Takemura, M., Higashino, M., Takada, N., Kishida, T., et.al. Bronchoscopic ultrasonography for staging supracarinal esophageal squamous cell carcinoma: impact on outcome, World J Surg, 2003. 27(5): p. 590-4., https://pubmed.ncbi.nlm.nih.gov/12715229/
176. Imadahl, A., Kirchner, R., Swoboda, L., Ruf, G., Is bronchoscopy a useful additional preoperative examination in esophageal carcinoma?, Langenbecks Arch Chir, 1990. 375(6): p. 326-9., https://pubmed.ncbi.nlm.nih.gov/2280646/
177. Nieveen van Dijkum, E. J., de Wit, L. T., van Delden, O. M., Rauws, E. A., van Lanschot, J. J., Obertop, H., et.al. The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors, Cancer, 1997. 79(7): p. 1315-9., https://pubmed.ncbi.nlm.nih.gov/9083152/
178. de Graaf, G. W., Ayantunde, A. A., Parsons, S. L., Duffy, J. P., Welch, N. T., The role of staging laparoscopy in oesophagogastric cancers, Eur J Surg Oncol, 2007. 33(8): p. 988-92., https://pubmed.ncbi.nlm.nih.gov/17344017/
179. Nath, J., Moorthy, K., Taniere, P., Hallissey, M., Alderson, D., Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma, Br J Surg, 2008. 95(6): p. 721-6., https://pubmed.ncbi.nlm.nih.gov/18412292/
180. Krasna, M. J., Reed, C. E., Jaklitsch, M. T., Cushing, D., Sugarbaker, D. J., Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons, Ann Thorac Surg, 1995. 60(5): p. 1337-40., https://pubmed.ncbi.nlm.nih.gov/8526623/
181. Krasna, M. J., Reed, C. E., Nedzwiecki, D., Hollis, D. R., Luketich, J. D., DeCamp, M. M., et.al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer, Ann Thorac Surg, 2001. 71(4): p. 1073-9., https://pubmed.ncbi.nlm.nih.gov/11308139/
182. Luketich, J. D., Friedman, D. M., Weigel, T. L., Meehan, M. A., Keenan, R. J., Townsend, D. W., et.al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans, Ann Thorac Surg, 1999. 68(4): p. 1133-6; discussion 1136-7., https://pubmed.ncbi.nlm.nih.gov/10543468/
183. Wang, G-Q, Abnet, C C, Shen, Q, Lewin, K J, Sun, X-D, Roth, M J, et.al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population, Gut, 2005. 54(2): p. 187-192., https://pubmed.ncbi.nlm.nih.gov/15647178/
184. Kuwano, H., Peculiar histopathologic features of esophageal cancer, Surg Today, 1998. 28(6): p. 573-5., https://pubmed.ncbi.nlm.nih.gov/9681603/
185. Bosman, FT., Carneiro, F., Hruban, RH., Theise, ND., WHO Classification of Tumors of the Digestive System., 4 th edition, IARC, Lyon, 2010.
186. Schnell, T. G., Sontag, S. J., Chejfec, G., Aranha, G., Metz, A., O'Connell, S., et.al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia, Gastroenterology, 2001. 120(7): p. 1607-19., https://pubmed.ncbi.nlm.nih.gov/11375943/
187. Reid, B. J., Haggitt, R. C., Rubin, C. E., Roth, G., Surawicz, C. M., Van Belle, G., et.al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus, Hum Pathol, 1988. 19(2): p. 166-78., https://pubmed.ncbi.nlm.nih.gov/3343032/
188. Skacel, M., Petras, R. E., Gramlich, T. L., Sigel, J. E., Richter, J. E., Goldblum, J. R., The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression, Am J Gastroenterol, 2000. 95(12): p. 3383-7., https://pubmed.ncbi.nlm.nih.gov/11151865/
189. Montgomery, E., Bronner, M. P., Goldblum, J. R., Greenson, J. K., Haber, M. M., Hart, J., et.al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation, Hum Pathol, 2001. 32(4): p. 368-78., https://pubmed.ncbi.nlm.nih.gov/11331953/
190. Ormsby, A. H., Petras, R. E., Henricks, W. H., Rice, T. W., Rybicki, L. A., Richter, J. E., et.al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma, Gut, 2002. 51(5): p. 671-6., https://pubmed.ncbi.nlm.nih.gov/12377805/
191. Kerkhof, M., van Dekken, H., Steyerberg, E. W., Meijer, G. A., Mulder, A. H., de Bruine, A., et.al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists, Histopathology, 2007. 50(7): p. 920-7., https://pubmed.ncbi.nlm.nih.gov/17543082/
192. Wani, S., Mathur, S. C., Curvers, W. L., Singh, V., Alvarez Herrero, L., Hall, S. B., et.al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia, Clin Gastroenterol Hepatol, 2010. 8(9): p. 783-8., https://pubmed.ncbi.nlm.nih.gov/20472096/
193. Weusten, B., Bisschops, R., Coron, E., Dinis-Ribeiro, M., Dumonceau, J. M., Esteban, J. M., et.al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement, Endoscopy, 2017. 49(2): p. 191-198., https://pubmed.ncbi.nlm.nih.gov/28122386/
194. Shaheen, N. J., Falk, G. W., Iyer, P. G., Gerson, L. B., ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus, Am J Gastroenterol, 2016. 111(1): p. 30-50; quiz 51., https://pubmed.ncbi.nlm.nih.gov/26526079/
195. Bennett, Cathy, Vakil, Nimish, Bergman, Jacques, Harrison, Rebecca, Odze, Robert, Vieth, Michael, et.al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process., Gastroenterology, 2012. 143(2): p. 336-46., https://pubmed.ncbi.nlm.nih.gov/22537613/
196. Brown, I. S., Whiteman, D. C., Lauwers, G. Y., Foveolar type dysplasia in Barrett esophagus, Mod Pathol, 2010. 23(6): p. 834-43., https://pubmed.ncbi.nlm.nih.gov/20228780/
197. Odze, R. D., What the gastroenterologist needs to know about the histology of Barrett's esophagus, Curr Opin Gastroenterol, 2011. 27(4): p. 389-96., https://pubmed.ncbi.nlm.nih.gov/21543978/
198. Rucker-Schmidt, R. L., Sanchez, C. A., Blount, P. L., Ayub, K., Li, X., Rabinovitch, P. S., et.al. Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study, Am J Surg Pathol, 2009. 33(6): p. 886-93., https://pubmed.ncbi.nlm.nih.gov/19194279/
199. Mahajan, D., Bennett, A. E., Liu, X., Bena, J., Bronner, M. P., Grading of gastric foveolar-type dysplasia in Barrett's esophagus, Mod Pathol, 2010. 23(1): p. 1-11., https://pubmed.ncbi.nlm.nih.gov/19838164/
200. Demicco, E. G., Farris, A. B., 3rd, Baba, Y., Agbor-Etang, B., Bergethon, K., Mandal, R., et.al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma, Mod Pathol, 2011. 24(9): p. 1177-90., https://pubmed.ncbi.nlm.nih.gov/21572404/
201. Chandrasoma, P., Makarewicz, K., Wickramasinghe, K., Ma, Y., Demeester, T., A proposal for a new validated histological definition of the gastroesophageal junction, Hum Pathol, 2006. 37(1): p. 40-7., https://pubmed.ncbi.nlm.nih.gov/16360414/
202. Sharma, P., Falk, G. W., Weston, A. P., Reker, D., Johnston, M., Sampliner, R. E., Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus, Clin Gastroenterol Hepatol, 2006. 4(5): p. 566-72., https://pubmed.ncbi.nlm.nih.gov/16630761/
203. Gatenby, P. A., Ramus, J. R., Caygill, C. P., Charlett, A., Winslet, M. C., Watson, A., Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus, Dis Esophagus, 2009. 22(2): p. 133-42., https://pubmed.ncbi.nlm.nih.gov/19018855/
204. Weston, A. P., Banerjee, S. K., Sharma, P., Tran, T. M., Richards, R., Cherian, R., p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression, Am J Gastroenterol, 2001. 96(5): p. 1355-62., https://pubmed.ncbi.nlm.nih.gov/11374668/
205. Reid, B. J., Levine, D. S., Longton, G., Blount, P. L., Rabinovitch, P. S., Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets, Am J Gastroenterol, 2000. 95(7): p. 1669-76., https://pubmed.ncbi.nlm.nih.gov/10925966/
206. Buttar, N. S., Wang, K. K., Leontovich, O., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., et.al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus, Gastroenterology, 2002. 122(4): p. 1101-12., https://pubmed.ncbi.nlm.nih.gov/11910360/
207. Montgomery, E., Bronner, M. P., Greenson, J. K., Haber, M. M., Hart, J., Lamps, L. W., et.al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up, Am J Gastroenterol, 2002. 97(1): p. 27-31., https://pubmed.ncbi.nlm.nih.gov/11808966/
208. Harrison, R., Perry, I., Haddadin, W., McDonald, S., Bryan, R., Abrams, K., et.al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies, Am J Gastroenterol, 2007. 102(6): p. 1154-61., https://pubmed.ncbi.nlm.nih.gov/17433019/
209. Wittekind, C., TNM Klassifikation maligner Tumoren, 8. AuflageWeinheim: Wiley-VCH, 2020.
210. Fritz A, Percy C, Jack A, al., et, International Classification of Diseases for oncology (ICD-O), 3rd ed. Geneva: WHO, WHO, 2000., https://www.who.int/standards/classifications/other-classifications/international-classification-of-diseases-for-oncology
211. Wittekind C, Asamura H, LH, Sobin, TNM Atlas. Illustrated guide to the TNM Classification of Malignant Tumours. 6th edition. Oxford: Wiley Blackwell, 2014.
212. Kodama, M., Kakegawa, T., Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan, Surgery, 1998. 123(4): p. 432-9., https://pubmed.ncbi.nlm.nih.gov/9551070/
213. Bollschweiler, E., Baldus, S. E., Schroder, W., Schneider, P. M., Holscher, A. H., Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?, J Surg Oncol, 2006. 94(5): p. 355-63., https://pubmed.ncbi.nlm.nih.gov/16967455/
214. Rice, T. W., Zuccaro, G., Jr., Adelstein, D. J., Rybicki, L. A., Blackstone, E. H., Goldblum, J. R., Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status, Ann Thorac Surg, 1998. 65(3): p. 787-92., https://pubmed.ncbi.nlm.nih.gov/9527214/
215. Davies, A. R., Gossage, J. A., Zylstra, J., Mattsson, F., Lagergren, J., Maisey, N., et.al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction, J Clin Oncol, 2014. 32(27): p. 2983-90., https://pubmed.ncbi.nlm.nih.gov/25071104/
216. ©, The American Heritage® Medical Dictionary Copyright, The American Heritage® Medical Dictionary Copyright ©, Houghton Mifflin Company., 2007.
217. Siewert, J. R., Stein, H. J., Classification of adenocarcinoma of the oesophagogastric junction, Br J Surg, 1998. 85(11): p. 1457-9., https://pubmed.ncbi.nlm.nih.gov/9823902/
218. Kato, H., Tachimori, Y., Watanabe, H., Iizuka, T., Evaluation of the new (1987) TNM classification for thoracic esophageal tumors, Int J Cancer, 1993. 53(2): p. 220-3., https://pubmed.ncbi.nlm.nih.gov/8425758/
219. Enzinger, P. C., Mayer, R. J., Esophageal cancer, N Engl J Med, 2003. 349(23): p. 2241-52., https://pubmed.ncbi.nlm.nih.gov/14657432/
220. HJ, Stein, von, Rahden BH, Esophageal cancer. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds.) Prognostic Factors in Cancer, Wiley-Liss, New York, 2006. 3rd ed.: p. pp. 125-128., https://www.wiley.com/en-us/Prognostic+Factors+in+Cancer%2C+3rd+Edition-p-9780470038017
221. Roder, J. D., Busch, R., Stein, H. J., Fink, U., Siewert, J. R., Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus, Br J Surg, 1994. 81(3): p. 410-3., https://pubmed.ncbi.nlm.nih.gov/8173915/
222. Hermanek, P., Tumors of the gastrointestinal tract and the pancreas: histopathology, staging and prognosis, Anticancer Res, 1999. 19(4a): p. 2393-6., https://pubmed.ncbi.nlm.nih.gov/10470164/
223. Dexter, S. P., Sue-Ling, H., McMahon, M. J., Quirke, P., Mapstone, N., Martin, I. G., Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer, Gut, 2001. 48(5): p. 667-70., https://pubmed.ncbi.nlm.nih.gov/11302966/
224. Khan, O. A., Fitzgerald, J. J., Soomro, I., Beggs, F. D., Morgan, W. E., Duffy, J. P., Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer, Br J Cancer, 2003. 88(10): p. 1549-52., https://pubmed.ncbi.nlm.nih.gov/12771920/
225. Brucher, B. L., Stein, H. J., Bartels, H., Feussner, H., Siewert, J. R., Achalasia and esophageal cancer: incidence, prevalence, and prognosis, World J Surg, 2001. 25(6): p. 745-9., https://pubmed.ncbi.nlm.nih.gov/11376410/
226. Sarbia, M., Porschen, R., Borchard, F., Horstmann, O., Willers, R., Gabbert, H. E., p53 protein expression and prognosis in squamous cell carcinoma of the esophagus, Cancer, 1994. 74(8): p. 2218-23., https://pubmed.ncbi.nlm.nih.gov/7922972/
227. Mandard, A. M., Dalibard, F., Mandard, J. C., Marnay, J., Henry-Amar, M., Petiot, J. F., et.al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations, Cancer, 1994. 73(11): p. 2680-6., https://pubmed.ncbi.nlm.nih.gov/8194005/
228. Becker, K., Mueller, J. D., Schulmacher, C., Ott, K., Fink, U., Busch, R., et.al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy, Cancer, 2003. 98(7): p. 1521-30., https://pubmed.ncbi.nlm.nih.gov/14508841/
229. Langer, R., Ott, K., Feith, M., Lordick, F., Siewert, J. R., Becker, K., Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas, Mod Pathol, 2009. 22(12): p. 1555-63., https://pubmed.ncbi.nlm.nih.gov/19801967/
230. Becker, K., Langer, R., Reim, D., Novotny, A., Meyer zum Buschenfelde, C., Engel, J., et.al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases, Ann Surg, 2011. 253(5): p. 934-9., https://pubmed.ncbi.nlm.nih.gov/21490451/
231. Langer, R., Becker, K., Zlobec, I., Gertler, R., Sisic, L., Buchler, M., et.al. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy, Ann Surg Oncol, 2014. 21(3): p. 915-21., https://pubmed.ncbi.nlm.nih.gov/24281419/
232. Mirza, A., Naveed, A., Hayes, S., Formela, L., Welch, I., West, C. M., et.al. Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant Chemotherapy: Which Scoring System to Use?, ISRN Pathology, 2012. 2012: p. 8., https://www.hindawi.com/journals/isrn/2012/519351/
233. Karamitopoulou, E., Thies, S., Zlobec, I., Ott, K., Feith, M., Slotta-Huspenina, J., et.al. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches, Am J Surg Pathol, 2014. 38(11): p. 1551-6., https://pubmed.ncbi.nlm.nih.gov/25140894/
234. Ryan, R, Gibbons, D, Hyland, JM, Treanor, D, White, A, Mulcahy, HE, et.al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer., Histopathology, 2005. 47 (2)(2): p. 141-6., https://pubmed.ncbi.nlm.nih.gov/16045774/
235. Amin, MB, Greene, FL, Edge, SB, Compton, CC, Gershenwald, JE, Brookland, RK, et.al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging., CA Cancer J Clin, 2017. 67 (2)(2): p. 93-99., https://pubmed.ncbi.nlm.nih.gov/28094848/
236. College of American Pathologists (CAP), Protocol for the Examination of Specimens From Patients With Carcinoma of the Esophagus., 2020., https://webapps.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Esophagus_12protocol_3111.pdf
237. Ancona, E., Ruol, A., Santi, S., Merigliano, S., Sileni, V. C., Koussis, H., et.al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone, Cancer, 2001. 91(11): p. 2165-74., https://pubmed.ncbi.nlm.nih.gov/11391598/
238. Rohatgi, P., Swisher, S. G., Correa, A. M., Wu, T. T., Liao, Z., Komaki, R., et.al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response, Cancer, 2005. 104(11): p. 2365-72., https://pubmed.ncbi.nlm.nih.gov/16245310/
239. Schneider, P. M., Baldus, S. E., Metzger, R., Kocher, M., Bongartz, R., Bollschweiler, E., et.al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification, Ann Surg, 2005. 242(5): p. 684-92., https://pubmed.ncbi.nlm.nih.gov/16244542/
240. Meredith, K. L., Weber, J. M., Turaga, K. K., Siegel, E. M., McLoughlin, J., Hoffe, S., et.al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer, Ann Surg Oncol, 2010. 17(4): p. 1159-67., https://pubmed.ncbi.nlm.nih.gov/20140529/
241. Chirieac, L. R., Swisher, S. G., Ajani, J. A., Komaki, R. R., Correa, A. M., Morris, J. S., et.al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation, Cancer, 2005. 103(7): p. 1347-55., https://pubmed.ncbi.nlm.nih.gov/15719440/
242. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., et.al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 2010. 376(9742): p. 687-97., https://pubmed.ncbi.nlm.nih.gov/20728210/
243. Bang, Y., Pathological features of advanced gastric cancer (GC): Relatationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27:15s, 2009., https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.4556
244. Satoh, T., Bang, Y. J., Gotovkin, E. A., Hamamoto, Y., Kang, Y. K., Moiseyenko, V. M., et.al. Quality of life in the trastuzumab for gastric cancer trial, Oncologist, 2014. 19(7): p. 712-9., https://pubmed.ncbi.nlm.nih.gov/24951609/
245. Arends et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin. Klinische Ernährung in der nicht-chirurgischen Onkologie. Aktuel Ernährungsmed in press, 2015.
246. Falkner, D., Plato, R., Weimann, A., Die Wertigkeit der Feinnadelkatheterjejunostomie in der postoperativen enteralen Ernährung nach Ösophagusresektion. Deutsche Gesellschaft für Chirurgie. 131. Kongress der Dt. Gesellschaft für Chirurgie. Berlin 25.-28.03.2014.
247. Saito, T., Kuwahara, A., Shigemitsu, Y., Kinoshita, T., Shimoda, K., Miyahara, M., et.al. Factors related to malnutrition in patients with esophageal cancer, Nutrition, 1991. 7(2): p. 117-21., https://pubmed.ncbi.nlm.nih.gov/1802192/
248. van Stijn, M. F., Korkic-Halilovic, I., Bakker, M. S., van der Ploeg, T., van Leeuwen, P. A., Houdijk, A. P., Preoperative nutrition status and postoperative outcome in elderly general surgery patients: a systematic review, JPEN J Parenter Enteral Nutr, 2013. 37(1): p. 37-43., https://pubmed.ncbi.nlm.nih.gov/22549764/
249. Weimann, A., Breitenstein, S., Breuer, J. P., Gabor, S. E., Holland-Cunz, S., Kemen, M., et.al. Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine, Chirurg, 2014. 85(4): p. 320-6., https://pubmed.ncbi.nlm.nih.gov/24718444/
250. Weimann, A., Meyer, H. J., Muller, M. J., Stenkhoff, P., Miholic, J., Jahne, J., et.al. Significance of preoperative weight loss for perioperative metabolic adaptation and surgical risk in patients with tumors of the upper gastrointestinal tract, Langenbecks Arch Chir, 1992. 377(1): p. 45-52., https://pubmed.ncbi.nlm.nih.gov/1569804/
251. Pech, O., Bollschweiler, E., Manner, H., Leers, J., Ell, C., Holscher, A. H., Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers, Ann Surg, 2011. 254(1): p. 67-72., https://pubmed.ncbi.nlm.nih.gov/21532466/
252. Prasad, G. A., Wu, T. T., Wigle, D. A., Buttar, N. S., Wongkeesong, L. M., Dunagan, K. T., et.al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus, Gastroenterology, 2009. 137(3): p. 815-23., https://pubmed.ncbi.nlm.nih.gov/19524578/
253. Ell, C., May, A., Gossner, L., Pech, O., Gunter, E., Mayer, G., et.al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus, Gastroenterology, 2000. 118(4): p. 670-7., https://pubmed.ncbi.nlm.nih.gov/10734018/
254. Ell, C., May, A., Pech, O., Gossner, L., Guenter, E., Behrens, A., et.al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer), Gastrointest Endosc, 2007. 65(1): p. 3-10., https://pubmed.ncbi.nlm.nih.gov/17185072/
255. Pech, O., Behrens, A., May, A., Nachbar, L., Gossner, L., Rabenstein, T., et.al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus, Gut, 2008. 57(9): p. 1200-1206., https://pubmed.ncbi.nlm.nih.gov/18460553/
256. Pech, O., May, A., Manner, H., Behrens, A., Pohl, J., Weferling, M., et.al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus, Gastroenterology, 2014. 146(3): p. 652-660.e1., https://pubmed.ncbi.nlm.nih.gov/24269290/
257. Chennat, J., Konda, V. J., Ross, A. S., de Tejada, A. H., Noffsinger, A., Hart, J., et.al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience, Am J Gastroenterol, 2009. 104(11): p. 2684-92., https://pubmed.ncbi.nlm.nih.gov/19690526/
258. Moss, A., Bourke, M. J., Hourigan, L. F., Gupta, S., Williams, S. J., Tran, K., et.al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit, Am J Gastroenterol, 2010. 105(6): p. 1276-83., https://pubmed.ncbi.nlm.nih.gov/20179694/
259. Pouw, R. E., Seewald, S., Gondrie, J. J., Deprez, P. H., Piessevaux, H., Pohl, H., et.al. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients, Gut, 2010. 59(9): p. 1169-77., https://pubmed.ncbi.nlm.nih.gov/20525701/
260. Pouw, R. E., Wirths, K., Eisendrath, P., Sondermeijer, C. M., Ten Kate, F. J., Fockens, P., et.al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia, Clin Gastroenterol Hepatol, 2010. 8(1): p. 23-9., https://pubmed.ncbi.nlm.nih.gov/19602454/
261. van Vilsteren, F. G., Pouw, R. E., Seewald, S., Alvarez Herrero, L., Sondermeijer, C. M., Visser, M., et.al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial, Gut, 2011. 60(6): p. 765-73., https://pubmed.ncbi.nlm.nih.gov/21209124/
262. Manner, H, May, A, Pech, O, Gossner, L, Rabenstein, T, Günter, E, et.al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent., Am J Gastroenterol, 2008. 103 (10)(10): p. 2589-97., https://pubmed.ncbi.nlm.nih.gov/18785950/
263. Manner, H., Pech, O., Heldmann, Y., May, A., Pohl, J., Behrens, A., et.al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion, Clin Gastroenterol Hepatol, 2013. 11(6): p. 630-5; quiz e45., https://pubmed.ncbi.nlm.nih.gov/23357492/
264. Alvarez Herrero, L., Pouw, R. E., van Vilsteren, F. G., ten Kate, F. J., Visser, M., van Berge Henegouwen, M. I., et.al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens, Endoscopy, 2010. 42(12): p. 1030-6., https://pubmed.ncbi.nlm.nih.gov/20960392/
265. Fitzgerald, R. C., di Pietro, M., Ragunath, K., Ang, Y., Kang, J. Y., Watson, P., et.al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus, Gut, 2014. 63(1): p. 7-42., https://pubmed.ncbi.nlm.nih.gov/24165758/
266. Guo, H. M., Zhang, X. Q., Chen, M., Huang, S. L., Zou, X. P., Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer, World J Gastroenterol, 2014. 20(18): p. 5540-7., https://pubmed.ncbi.nlm.nih.gov/24833885/
267. Neuhaus, H., Terheggen, G., Rutz, E. M., Vieth, M., Schumacher, B., Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus, Endoscopy, 2012. 44(12): p. 1105-13., https://pubmed.ncbi.nlm.nih.gov/22968641/
268. Kagemoto, K., Oka, S., Tanaka, S., Miwata, T., Urabe, Y., Sanomura, Y., et.al. Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma, Gastrointest Endosc, 2014. 80(2): p. 239-45., https://pubmed.ncbi.nlm.nih.gov/24565073/
269. Probst, A., Maerkl, B., Anthuber, M., Messmann, H., Endoskopische Submukosadissektion (ESD) im Ösophagus, Z Gastroenterol, 2013. 51(08): p. K233.
270. Feith, M., Stein, H. J., Siewert, J. R., Pattern of lymphatic spread of Barrett's cancer, World J Surg, 2003. 27(9): p. 1052-7., https://pubmed.ncbi.nlm.nih.gov/12917758/
271. Holscher, A. H., Bollschweiler, E., Schroder, W., Metzger, R., Gutschow, C., Drebber, U., Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer, Ann Surg, 2011. 254(5): p. 802-7; discussion 807-8., https://pubmed.ncbi.nlm.nih.gov/22042472/
272. Zemler, B., May, A., Ell, C., Stolte, M., Early Barrett's carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion, Virchows Arch, 2010. 456(6): p. 609-14., https://pubmed.ncbi.nlm.nih.gov/20449614/
273. Buskens, C. J., Westerterp, M., Lagarde, S. M., Bergman, J. J., ten Kate, F. J., van Lanschot, J. J., Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features, Gastrointest Endosc, 2004. 60(5): p. 703-10., https://pubmed.ncbi.nlm.nih.gov/15557945/
274. Westerterp, M., Koppert, L. B., Buskens, C. J., Tilanus, H. W., ten Kate, F. J., Bergman, J. J., et.al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction, Virchows Arch, 2005. 446(5): p. 497-504., https://pubmed.ncbi.nlm.nih.gov/15838647/
275. Ancona, E., Rampado, S., Cassaro, M., Battaglia, G., Ruol, A., Castoro, C., et.al. Prediction of lymph node status in superficial esophageal carcinoma, Ann Surg Oncol, 2008. 15(11): p. 3278-88., https://pubmed.ncbi.nlm.nih.gov/18726651/
276. Liu, L., Hofstetter, W. L., Rashid, A., Swisher, S. G., Correa, A. M., Ajani, J. A., et.al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma, Am J Surg Pathol, 2005. 29(8): p. 1079-85., https://pubmed.ncbi.nlm.nih.gov/16006804/
277. Sepesi, B., Watson, T. J., Zhou, D., Polomsky, M., Litle, V. R., Jones, C. E., et.al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens, J Am Coll Surg, 2010. 210(4): p. 418-27., https://pubmed.ncbi.nlm.nih.gov/20347733/
278. Badreddine, R. J., Prasad, G. A., Lewis, J. T., Lutzke, L. S., Borkenhagen, L. S., Dunagan, K. T., et.al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma, Clin Gastroenterol Hepatol, 2010. 8(3): p. 248-53., https://pubmed.ncbi.nlm.nih.gov/19948247/
279. Griffin, S. M., Burt, A. D., Jennings, N. A., Lymph node metastasis in early esophageal adenocarcinoma, Ann Surg, 2011. 254(5): p. 731-6; discussion 736-7., https://pubmed.ncbi.nlm.nih.gov/21997815/
280. Leers, J. M., DeMeester, S. R., Oezcelik, A., Klipfel, N., Ayazi, S., Abate, E., et.al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens, Ann Surg, 2011. 253(2): p. 271-8., https://pubmed.ncbi.nlm.nih.gov/21119508/
281. Lorenz, D., Origer, J., Pauthner, M., Graupe, F., Fisseler-Eckhoff, A., Stolte, M., et.al. Prognostic risk factors of early esophageal adenocarcinomas, Ann Surg, 2014. 259(3): p. 469-76., https://pubmed.ncbi.nlm.nih.gov/24096754/
282. May, A., Gossner, L., Pech, O., Fritz, A., Gunter, E., Mayer, G., et.al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach, Eur J Gastroenterol Hepatol, 2002. 14(10): p. 1085-91., https://pubmed.ncbi.nlm.nih.gov/12362099/
283. Gossner, L., Stolte, M., Sroka, R., Rick, K., May, A., Hahn, E. G., et.al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid, Gastroenterology, 1998. 114(3): p. 448-55., https://pubmed.ncbi.nlm.nih.gov/9496934/
284. Pech, O., Gossner, L., May, A., Rabenstein, T., Vieth, M., Stolte, M., et.al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia, Gastrointest Endosc, 2005. 62(1): p. 24-30., https://pubmed.ncbi.nlm.nih.gov/15990815/
285. Overholt, B. F., Wang, K. K., Burdick, J. S., Lightdale, C. J., Kimmey, M., Nava, H. R., et.al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia, Gastrointest Endosc, 2007. 66(3): p. 460-8., https://pubmed.ncbi.nlm.nih.gov/17643436/
286. Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., et.al. Radiofrequency ablation in Barrett's esophagus with dysplasia, N Engl J Med, 2009. 360(22): p. 2277-88., https://pubmed.ncbi.nlm.nih.gov/19474425/
287. Shaheen, N. J., Overholt, B. F., Sampliner, R. E., Wolfsen, H. C., Wang, K. K., Fleischer, D. E., et.al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia, Gastroenterology, 2011. 141(2): p. 460-8., https://pubmed.ncbi.nlm.nih.gov/21679712/
288. Ganz, R. A., Overholt, B. F., Sharma, V. K., Fleischer, D. E., Shaheen, N. J., Lightdale, C. J., et.al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry, Gastrointest Endosc, 2008. 68(1): p. 35-40., https://pubmed.ncbi.nlm.nih.gov/18355819/
289. Phoa, K. N., Pouw, R. E., van Vilsteren, F. G., Sondermeijer, C. M., Ten Kate, F. J., Visser, M., et.al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study, Gastroenterology, 2013. 145(1): p. 96-104., https://pubmed.ncbi.nlm.nih.gov/23542068/
290. Orman, E. S., Kim, H. P., Bulsiewicz, W. J., Cotton, C. C., Dellon, E. S., Spacek, M. B., et.al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation, Am J Gastroenterol, 2013. 108(2): p. 187-95; quiz 196., https://pubmed.ncbi.nlm.nih.gov/23247578/
291. Van Laethem, J. L., Jagodzinski, R., Peny, M. O., Cremer, M., Deviere, J., Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma, Endoscopy, 2001. 33(3): p. 257-61., https://pubmed.ncbi.nlm.nih.gov/11293760/
292. Ragunath, K., Krasner, N., Raman, V. S., Haqqani, M. T., Phillips, C. J., Cheung, I., Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness, Scand J Gastroenterol, 2005. 40(7): p. 750-8., https://pubmed.ncbi.nlm.nih.gov/16118910/
293. Kelty, C. J., Ackroyd, R., Brown, N. J., Stephenson, T. J., Stoddard, C. J., Reed, M. W., Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation, Aliment Pharmacol Ther, 2004. 20(11-12): p. 1289-96., https://pubmed.ncbi.nlm.nih.gov/15606390/
294. Dumot, J. A., Vargo, J. J., 2nd, Falk, G. W., Frey, L., Lopez, R., Rice, T. W., An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients, Gastrointest Endosc, 2009. 70(4): p. 635-44., https://pubmed.ncbi.nlm.nih.gov/19559428/
295. Shaheen, N. J., Greenwald, B. D., Peery, A. F., Dumot, J. A., Nishioka, N. S., Wolfsen, H. C., et.al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia, Gastrointest Endosc, 2010. 71(4): p. 680-5., https://pubmed.ncbi.nlm.nih.gov/20363409/
296. Ishihara, R., Iishi, H., Uedo, N., Takeuchi, Y., Yamamoto, S., Yamada, T., et.al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan, Gastrointest Endosc, 2008. 68(6): p. 1066-72., https://pubmed.ncbi.nlm.nih.gov/18620345/
297. Cao, Y., Liao, C., Tan, A., Gao, Y., Mo, Z., Gao, F., Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract, Endoscopy, 2009. 41(9): p. 751-7., https://pubmed.ncbi.nlm.nih.gov/19693750/
298. Srivastava, A., Hornick, J. L., Li, X., Blount, P. L., Sanchez, C. A., Cowan, D. S., et.al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus, Am J Gastroenterol, 2007. 102(3): p. 483-93; quiz 694., https://pubmed.ncbi.nlm.nih.gov/17338734/
299. Phoa, K. N., van Vilsteren, F. G., Weusten, B. L., Bisschops, R., Schoon, E. J., Ragunath, K., et.al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial, Jama, 2014. 311(12): p. 1209-17., https://pubmed.ncbi.nlm.nih.gov/24668102/
300. McCann, P., Stafinski, T., Wong, C., Menon, D., The safety and effectiveness of endoscopic and non-endoscopic approaches to the management of early esophageal cancer: a systematic review (Structured abstract), Cancer Treatment.Reviews., 2011. 1:, https://pubmed.ncbi.nlm.nih.gov/20570442/
301. Haidry, R. J., Butt, M. A., Dunn, J., Banks, M., Gupta, A., Smart, H., et.al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry, World J Gastroenterol, 2013. 19(36): p. 6011-9., https://pubmed.ncbi.nlm.nih.gov/24106401/
302. Min, B. H., Kim, E. R., Lee, J. H., Kang, K. J., Rhee, P. L., Kim, J. J., et.al. Feasibility and efficacy of argon plasma coagulation for early esophageal squamous cell neoplasia, Endoscopy, 2013. 45(7): p. 575-8., https://pubmed.ncbi.nlm.nih.gov/23801315/
303. Tahara, K., Tanabe, S., Ishido, K., Higuchi, K., Sasaki, T., Katada, C., et.al. Argon plasma coagulation for superficial esophageal squamous-cell carcinoma in high-risk patients, World J Gastroenterol, 2012. 18(38): p. 5412-7., https://pubmed.ncbi.nlm.nih.gov/23082058/
304. Peters, F. P., Kara, M. A., Rosmolen, W. D., Aalders, M. C., Ten Kate, F. J., Bultje, B. C., et.al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus, Gastrointest Endosc, 2005. 61(4): p. 506-14., https://pubmed.ncbi.nlm.nih.gov/15812401/
305. Metzger, R., Bollschweiler, E., Vallbohmer, D., Maish, M., DeMeester, T. R., Holscher, A. H., High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?, Dis Esophagus, 2004. 17(4): p. 310-4., https://pubmed.ncbi.nlm.nih.gov/15569369/
306. Holscher, A. H., Metzger, R., Brabender, J., Vallbohmer, D., Bollschweiler, E., High-volume centers--effect of case load on outcome in cancer surgery, Onkologie, 2004. 27(4): p. 412-6., https://pubmed.ncbi.nlm.nih.gov/15347901/
307. Coupland, V. H., Lagergren, J., Luchtenborg, M., Jack, R. H., Allum, W., Holmberg, L., et.al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008, Gut, 2013. 62(7): p. 961-6., https://pubmed.ncbi.nlm.nih.gov/23086798/
308. Brusselaers, N., Mattsson, F., Lagergren, J., Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis, Gut, 2014. 63(9): p. 1393-400., https://pubmed.ncbi.nlm.nih.gov/24270368/
309. Derogar, M., Sadr-Azodi, O., Johar, A., Lagergren, P., Lagergren, J., Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study, J Clin Oncol, 2013. 31(5): p. 551-7., https://pubmed.ncbi.nlm.nih.gov/23295792/
310. Reames, B. N., Shubeck, S. P., Birkmeyer, J. D., Strategies for reducing regional variation in the use of surgery: a systematic review, Ann Surg, 2014. 259(4): p. 616-27., https://pubmed.ncbi.nlm.nih.gov/24240626/
311. Nimptsch, U., Haist, T., Krautz, C., Grutzmann, R., Mansky, T., Lorenz, D., Hospital Volume, In-Hospital Mortality, and Failure to Rescue in Esophageal Surgery, Dtsch Arztebl Int, 2018. 115(47): p. 793-800., https://www.ncbi.nlm.nih.gov/pubmed/30636674
312. Hoeppner, J, Plum, PS, Buhr, H, Gockel, I, Lorenz, D, Ghadimi, M, et.al. [Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment]., Chirurg, 2021. 92 (4)(4): p. 350-360., https://pubmed.ncbi.nlm.nih.gov/32876700/
313. van der Werf, LR, Busweiler, LAD, van Sandick, JW, van Berge Henegouwen, MI, Wijnhoven, BPL, Reporting National Outcomes After Esophagectomy and Gastrectomy According to the Esophageal Complications Consensus Group (ECCG)., Ann Surg, 2020. 271 (6)(6): p. 1095-1101., https://pubmed.ncbi.nlm.nih.gov/30676381/
314. Schroder, W., Bollschweiler, E., Kossow, C., Holscher, A. H., Preoperative risk analysis--a reliable predictor of postoperative outcome after transthoracic esophagectomy?, Langenbecks Arch Surg, 2006. 391(5): p. 455-60., https://pubmed.ncbi.nlm.nih.gov/16896830/
315. Bollschweiler, E., Schroder, W., Holscher, A. H., Siewert, J. R., Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus, Br J Surg, 2000. 87(8): p. 1106-10., https://pubmed.ncbi.nlm.nih.gov/10931059/
316. Lagarde, S. M., Maris, A. K., de Castro, S. M., Busch, O. R., Obertop, H., van Lanschot, J. J., Evaluation of O-POSSUM in predicting in-hospital mortality after resection for oesophageal cancer, Br J Surg, 2007. 94(12): p. 1521-6., https://pubmed.ncbi.nlm.nih.gov/17929231/
317. Hodari, A., Hammoud, Z. T., Borgi, J. F., Tsiouris, A., Rubinfeld, I. S., Assessment of morbidity and mortality after esophagectomy using a modified frailty index, Ann Thorac Surg, 2013. 96(4): p. 1240-5., https://pubmed.ncbi.nlm.nih.gov/23915593/
318. Moehler, M., Al-Batran, S. E., Andus, T., Anthuber, M., Arends, J., Arnold, D., et.al. [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"], Z Gastroenterol, 2011. 49(4): p. 461-531., https://www.ncbi.nlm.nih.gov/pubmed/21476183
319. Briez N, et al. Is minimally invasive oesophagectomy for cancer decreasing pulmonary complications-Results from a case-control study., J Clin Oncol 28:15s,2010, 2010., https://www.researchgate.net/publication/313944127_Is_minimally_invasive_oesophagectomy_for_cancer_decreasing_pulmonary_complications_Results_from_a_case-control_study
320. Mariette, C., Markar, S. R., Dabakuyo-Yonli, T. S., Meunier, B., Pezet, D., Collet, D., et.al. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer, N Engl J Med, 2019. 380(2): p. 152-162., https://www.ncbi.nlm.nih.gov/pubmed/30625052
321. Mariette, C., Markar, S., Dabakuyo-Yonli, T. S., Meunier, B., Pezet, D., Collet, D., et.al. Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial, Ann Surg, 2020. 271(6): p. 1023-1029., https://www.ncbi.nlm.nih.gov/pubmed/31404005
322. Glatz, T., Marjanovic, G., Kulemann, B., Sick, O., Hopt, U. T., Hoeppner, J., Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients, Langenbecks Arch Surg, 2017. 402(2): p. 323-331., https://www.ncbi.nlm.nih.gov/pubmed/28083680
323. Yang, J., Chen, L., Ge, K., Yang, J. L., Efficacy of hybrid minimally invasive esophagectomy vs open esophagectomy for esophageal cancer: A meta-analysis, World J Gastrointest Oncol, 2019. 11(11): p. 1081-1091., https://www.ncbi.nlm.nih.gov/pubmed/31798787
324. Gottlieb-Vedi, E., Kauppila, J. H., Malietzis, G., Nilsson, M., Markar, S. R., Lagergren, J., Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis, Ann Surg, 2019. 270(6): p. 1005-1017., https://www.ncbi.nlm.nih.gov/pubmed/30817355
325. Maas, K. W., Cuesta, M. A., van Berge Henegouwen, M. I., Roig, J., Bonavina, L., Rosman, C., et.al. Quality of Life and Late Complications After Minimally Invasive Compared to Open Esophagectomy: Results of a Randomized Trial, World J Surg, 2015. 39(8): p. 1986-93., https://www.ncbi.nlm.nih.gov/pubmed/26037024
326. Straatman, J., van der Wielen, N., Cuesta, M. A., Daams, F., Roig Garcia, J., Bonavina, L., et.al. Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial, Ann Surg, 2017., https://pubmed.ncbi.nlm.nih.gov/28187044/
327. Pottgen, C., Stuschke, M., Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials, Cancer Treat.Rev., 2012. 38(6): p. 599-604., https://pubmed.ncbi.nlm.nih.gov/22116018/
328. Markar, S. R., Karthikesalingam, A., Penna, M., Low, D. E., Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis, Ann Surg Oncol, 2014. 21(3): p. 922-31., https://pubmed.ncbi.nlm.nih.gov/24212722/
329. Hofstetter, W. L., Salvage esophagectomy, J Thorac Dis, 2014. 6 Suppl 3: p. S341-9., https://pubmed.ncbi.nlm.nih.gov/24876940/
330. Wu, J., Chen, Q. X., Teng, L. S., Krasna, M. J., Prognostic significance of positive circumferential resection margin in esophageal cancer: a systematic review and meta-analysis, Ann Thorac Surg, 2014. 97(2): p. 446-53., https://pubmed.ncbi.nlm.nih.gov/24365211/
331. Holscher, A. H., Schroder, W., Bollschweiler, E., Beckurts, K. T., Schneider, P. M., How safe is high intrathoracic esophagogastrostomy ?, Chirurg, 2003. 74(8): p. 726-33., https://pubmed.ncbi.nlm.nih.gov/12928793/
332. Holscher, A. H., Schneider, P. M., Gutschow, C., Schroder, W., Laparoscopic ischemic conditioning of the stomach for esophageal replacement, Ann Surg, 2007. 245(2): p. 241-6., https://pubmed.ncbi.nlm.nih.gov/17245177/
333. Li, B., Xiang, J., Zhang, Y., Li, H., Zhang, J., Sun, Y., et.al. Comparison of Ivor-Lewis vs Sweet esophagectomy for esophageal squamous cell carcinoma: a randomized clinical trial, JAMA Surg, 2015. 150(4): p. 292-8., https://pubmed.ncbi.nlm.nih.gov/25650816/
334. Schroder, W., Vallbohmer, D., Bludau, M., Banczyk, A., Gutschow, C., Holscher, A. H., The resection of the azygos vein--necessary or redundant extension of transthoracic esophagectomy?, J Gastrointest Surg, 2008. 12(7): p. 1163-7., https://pubmed.ncbi.nlm.nih.gov/18278537/
335. Boone, J., Schipper, M. E., Bleys, R. L., Borel Rinkes, I. H., van Hillegersberg, R., The effect of azygos vein preservation on mediastinal lymph node harvesting in thoracic esophagolymphadenectomy, Dis Esophagus, 2008. 21(3): p. 226-9., https://pubmed.ncbi.nlm.nih.gov/18430103/
336. Siewert, J. R., Holscher, A. H., Becker, K., Gossner, W., Cardia cancer: attempt at a therapeutically relevant classification, Chirurg, 1987. 58(1): p. 25-32., https://pubmed.ncbi.nlm.nih.gov/3829805/
337. Kutup, A., Nentwich, M. F., Bollschweiler, E., Bogoevski, D., Izbicki, J. R., Holscher, A. H., What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy, Ann Surg, 2014. 260(6): p. 1016-22., https://pubmed.ncbi.nlm.nih.gov/24950288/
338. Omloo, J. M., Lagarde, S. M., Hulscher, J. B., Reitsma, J. B., Fockens, P., van Dekken, H., et.al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial, Ann Surg, 2007. 246(6): p. 992-1000; discussion 1000-1., https://pubmed.ncbi.nlm.nih.gov/18043101/
339. Workum, F, Maas, J, Wildenberg, Fjh, Polat, F, Kouwenhoven, Ea, Det, Mj, et.al. Improved Functional Results After Minimally Invasive Esophagectomy: intrathoracic Versus Cervical Anastomosis, Annals of thoracic surgery, 2017. 103(1): p. 267-273., https://pubmed.ncbi.nlm.nih.gov/27677565/
340. Deng, J., Su, Q., Ren, Z., Wen, J., Xue, Z., Zhang, L., et.al. Comparison of short-term outcomes between minimally invasive McKeown and Ivor Lewis esophagectomy for esophageal or junctional cancer: a systematic review and meta-analysis, Onco Targets Ther, 2018. 11: p. 6057-6069., https://www.ncbi.nlm.nih.gov/pubmed/30275710
341. Low, D. E., Kuppusamy, M. K., Alderson, D., Cecconello, I., Chang, A. C., Darling, G., et.al. Benchmarking Complications Associated with Esophagectomy, Ann Surg, 2019. 269(2): p. 291-298., https://www.ncbi.nlm.nih.gov/pubmed/29206677
342. Low, D. E., Alderson, D., Cecconello, I., Chang, A. C., Darling, G. E., D'Journo, X. B., et.al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG), Ann Surg, 2015. 262(2): p. 286-94., https://www.ncbi.nlm.nih.gov/pubmed/25607756
343. Gooszen, J. A. H., Goense, L., Gisbertz, S. S., Ruurda, J. P., van Hillegersberg, R., van Berge Henegouwen, M. I., Intrathoracic versus cervical anastomosis and predictors of anastomotic leakage after oesophagectomy for cancer, Br J Surg, 2018. 105(5): p. 552-560., https://www.ncbi.nlm.nih.gov/pubmed/29412450
344. Hayata, K., Nakamori, M., Nakamura, M., Ojima, T., Iwahashi, M., Katsuda, M., et.al. Circular stapling versus triangulating stapling for the cervical esophagogastric anastomosis after esophagectomy in patients with thoracic esophageal cancer: A prospective, randomized, controlled trial, Surgery, 2017. 162(1): p. 131-138., https://www.ncbi.nlm.nih.gov/pubmed/28318550
345. Sasako, M., Sano, T., Yamamoto, S., Sairenji, M., Arai, K., Kinoshita, T., et.al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial, Lancet Oncol, 2006. 7(8): p. 644-51., https://pubmed.ncbi.nlm.nih.gov/16887481/
346. Kurokawa, Y, Sasako, M, Sano, T, Yoshikawa, T, Iwasaki, Y, Nashimoto, A, et.al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia, British journal of surgery, 2015. 102(4): p. 341-348., https://pubmed.ncbi.nlm.nih.gov/25605628/
347. Li, B., Hu, H., Zhang, Y., Zhang, J., Miao, L., Ma, L., et.al. Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial, Ann Surg, 2018. 267(5): p. 826-832., https://www.ncbi.nlm.nih.gov/pubmed/28448385
348. Peyre, C. G., Hagen, J. A., DeMeester, S. R., Altorki, N. K., Ancona, E., Griffin, S. M., et.al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection, Ann Surg, 2008. 248(4): p. 549-56., https://pubmed.ncbi.nlm.nih.gov/18936567/
349. Peyre, C. G., Hagen, J. A., DeMeester, S. R., Van Lanschot, J. J., Holscher, A., Law, S., et.al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes, Ann Surg, 2008. 248(6): p. 979-85., https://pubmed.ncbi.nlm.nih.gov/19092342/
350. Lerut, T., Nafteux, P., Moons, J., Coosemans, W., Decker, G., De Leyn, P., et.al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma, Ann Surg, 2004. 240(6): p. 962-72; discussion 972-4., https://pubmed.ncbi.nlm.nih.gov/15570202/
351. Rizk, N. P., Ishwaran, H., Rice, T. W., Chen, L. Q., Schipper, P. H., Kesler, K. A., et.al. Optimum lymphadenectomy for esophageal cancer, Ann Surg, 2010. 251(1): p. 46-50., https://pubmed.ncbi.nlm.nih.gov/20032718/
352. Fujita, H., Sueyoshi, S., Tanaka, T., Fujii, T., Toh, U., Mine, T., et.al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy, World J Surg, 2003. 27(5): p. 571-9., https://pubmed.ncbi.nlm.nih.gov/12715226/
353. Peyre, C. G., Hagen, J. A., DeMeester, S. R., Altorki, N. K., Ancona, E., Griffin, S. M., et.al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection, Ann Surg, 2008. 248(4): p. 549-56., https://www.ncbi.nlm.nih.gov/pubmed/18936567
354. Visser, E., Markar, S. R., Ruurda, J. P., Hanna, G. B., van Hillegersberg, R., Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients: A Systematic Review and Meta-analysis, Ann Surg, 2019. 269(2): p. 261-268., https://www.ncbi.nlm.nih.gov/pubmed/29794846
355. Bollschweiler, E., Baldus, S. E., Schroder, W., Schneider, P. M., Holscher, A. H., Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?, J Surg Oncol, 2006. 94(5): p. 355-63., https://www.ncbi.nlm.nih.gov/pubmed/16967455
356. Bollschweiler, E., Besch, S., Drebber, U., Schroder, W., Monig, S. P., Vallbohmer, D., et.al. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer, Ann.Surg.Oncol., 2010. 17(12): p. 3187-3194., https://pubmed.ncbi.nlm.nih.gov/20585867/
357. Bekkar, S., Gronnier, C., Messager, M., Robb, W. B., Piessen, G., Mariette, C., The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma, Ann Thorac Surg, 2014. 97(1): p. 303-10., https://pubmed.ncbi.nlm.nih.gov/24200394/
358. Mariette, C., Carneiro, F., Grabsch, H. I., van der Post, R. S., Allum, W., de Manzoni, G., et.al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma, Gastric Cancer, 2019. 22(1): p. 1-9., https://www.ncbi.nlm.nih.gov/pubmed/30167905
359. Yamashita, H., Seto, Y., Sano, T., Makuuchi, H., Ando, N., Sasako, M., et.al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma, Gastric Cancer, 2017. 20(Suppl 1): p. 69-83., https://www.ncbi.nlm.nih.gov/pubmed/27796514
360. Kurokawa, Y., Takeuchi, H., Doki, Y., Mine, S., Terashima, M., Yasuda, T., et.al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study, Ann Surg, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31404008
361. Holscher, A. H., Law, S., Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers, Gastric Cancer, 2020. 23(1): p. 3-9., https://www.ncbi.nlm.nih.gov/pubmed/31691875
362. Hosoda, K., Washio, M., Mieno, H., Moriya, H., Ema, A., Ushiku, H., et.al. Comparison of double-flap and OrVil techniques of laparoscopy-assisted proximal gastrectomy in preventing gastroesophageal reflux: a retrospective cohort study, Langenbecks Arch Surg, 2019. 404(1): p. 81-91., https://www.ncbi.nlm.nih.gov/pubmed/30612151
363. Zapletal, Ch, Heesen, Ch, Origer, J., Pauthner, M., Pech, O., Ell, Ch, et.al. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection, World J Surg, 2014. 38(6): p. 1444-52., https://www.ncbi.nlm.nih.gov/pubmed/24378548
364. Holscher, A., Berlth, F., Hemmerich, M., Minot, S., Schmidt, H., [Double Tract Reconstruction Following Limited Oesophagogastric Resection of AEG Types II and III Adenocarcinomas], Zentralbl Chir, 2020. 145(1): p. 35-40., https://www.ncbi.nlm.nih.gov/pubmed/31100761
365. Holscher, A. H., Schroder, W., Bollschweiler, E., Beckurts, K. T., Schneider, P. M., [How safe is high intrathoracic esophagogastrostomy?], Chirurg, 2003. 74(8): p. 726-33., https://www.ncbi.nlm.nih.gov/pubmed/12928793
366. Holscher, A. H., Schneider, P. M., Gutschow, C., Schroder, W., Laparoscopic ischemic conditioning of the stomach for esophageal replacement, Ann Surg, 2007. 245(2): p. 241-6., https://www.ncbi.nlm.nih.gov/pubmed/17245177
367. van der Sluis, P. C., van der Horst, S., May, A. M., Schippers, C., Brosens, L. A. A., Joore, H. C. A., et.al. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial, Ann Surg, 2019. 269(4): p. 621-630., https://www.ncbi.nlm.nih.gov/pubmed/30308612
368. Schroder, W., Holscher, A. H., Bludau, M., Vallbohmer, D., Bollschweiler, E., Gutschow, C., Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit, World J Surg, 2010. 34(4): p. 738-43., https://pubmed.ncbi.nlm.nih.gov/20098986/
369. Urschel, J. D., Blewett, C. J., Young, J. E., Miller, J. D., Bennett, W. F., Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials, Dig Surg, 2002. 19(3): p. 160-4., https://pubmed.ncbi.nlm.nih.gov/12119515/
370. Gaur, P., Swanson, S. J., Should we continue to drain the pylorus in patients undergoing an esophagectomy?, Dis Esophagus, 2014. 27(6): p. 568-73., https://pubmed.ncbi.nlm.nih.gov/23442059/
371. Hadzijusufovic, E., Tagkalos, E., Neumann, H., Babic, B., Heinrich, S., Lang, H., et.al. Preoperative endoscopic pyloric balloon dilatation decreases the rate of delayed gastric emptying after Ivor-Lewis esophagectomy, Dis Esophagus, 2019. 32(6):, https://www.ncbi.nlm.nih.gov/pubmed/30508077
372. Vallbohmer, D., Holscher, A. H., Herbold, T., Gutschow, C., Schroder, W., Diaphragmatic hernia after conventional or laparoscopic-assisted transthoracic esophagectomy, Ann Thorac Surg, 2007. 84(6): p. 1847-52., https://pubmed.ncbi.nlm.nih.gov/18036896/
373. Price, T. N., Nichols, F. C., Harmsen, W. S., Allen, M. S., Cassivi, S. D., Wigle, D. A., et.al. A comprehensive review of anastomotic technique in 432 esophagectomies, Ann Thorac Surg, 2013. 95(4): p. 1154-60; discussion 1160-1., https://pubmed.ncbi.nlm.nih.gov/23395626/
374. Erkmen, C. P., Raman, V., Ghushe, N. D., Trus, T. L., Laparoscopic repair of hiatal hernia after esophagectomy, J Gastrointest Surg, 2013. 17(8): p. 1370-4., https://pubmed.ncbi.nlm.nih.gov/23797880/
375. Maas, K. W., Cuesta, M. A., van Berge Henegouwen, M. I., Roig, J., Bonavina, L., Rosman, C., et.al. Quality of Life and Late Complications After Minimally Invasive Compared to Open Esophagectomy: Results of a Randomized Trial, World J Surg, 2015. 39(8): p. 1986-93., https://pubmed.ncbi.nlm.nih.gov/26037024/
376. Luketich, J. D., Pennathur, A., Awais, O., Levy, R. M., Keeley, S., Shende, M., et.al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients, Ann Surg, 2012. 256(1): p. 95-103., https://pubmed.ncbi.nlm.nih.gov/22668811/
377. Smithers, B. M., Gotley, D. C., Martin, I., Thomas, J. M., Comparison of the outcomes between open and minimally invasive esophagectomy, Ann Surg, 2007. 245(2): p. 232-40., https://pubmed.ncbi.nlm.nih.gov/17245176/
378. Briez, N., Piessen, G., Torres, F., Lebuffe, G., Triboulet, J. P., Mariette, C., Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications, Br J Surg, 2012. 99(11): p. 1547-53., https://pubmed.ncbi.nlm.nih.gov/23027071/
379. Harbison, G. J., Vossler, J. D., Yim, N. H., Murayama, K. M., Outcomes of robotic versus non-robotic minimally-invasive esophagectomy for esophageal cancer: An American College of Surgeons NSQIP database analysis, Am J Surg, 2019. 218(6): p. 1223-1228., https://www.ncbi.nlm.nih.gov/pubmed/31500797
380. Jin, D., Yao, L., Yu, J., Liu, R., Guo, T., Yang, K., et.al. Robotic-assisted minimally invasive esophagectomy versus the conventional minimally invasive one: A meta-analysis and systematic review, Int J Med Robot, 2019. 15(3): p. e1988., https://www.ncbi.nlm.nih.gov/pubmed/30737881
381. Espinoza-Mercado, F., Imai, T. A., Borgella, J. D., Sarkissian, A., Serna-Gallegos, D., Alban, R. F., et.al. Does the Approach Matter? Comparing Survival in Robotic, Minimally Invasive, and Open Esophagectomies, Ann Thorac Surg, 2019. 107(2): p. 378-385., https://www.ncbi.nlm.nih.gov/pubmed/30312615
382. Mariette, C., Markar, S., Dabakuyo-Yonli, T. S., Meunier, B., Pezet, D., Collet, D., et.al. Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial, Ann Surg, 2020. 271(6): p. 1023-1029., https://www.ncbi.nlm.nih.gov/pubmed/31404005
383. Bonavina, L., Scolari, F., Aiolfi, A., Bonitta, G., Sironi, A., Saino, G., et.al. Early outcome of thoracoscopic and hybrid esophagectomy: Propensity-matched comparative analysis, Surgery, 2016. 159(4): p. 1073-81., https://pubmed.ncbi.nlm.nih.gov/26422764/
384. Metcalfe, C., Avery, K., Berrisford, R., Barham, P., Noble, S. M., Fernandez, A. M., et.al. Comparing open and minimally invasive surgical procedures for oesophagectomy in the treatment of cancer: the ROMIO (Randomised Oesophagectomy: Minimally Invasive or Open) feasibility study and pilot trial, Health Technol Assess, 2016. 20(48): p. 1-68., https://www.ncbi.nlm.nih.gov/pubmed/27373720
385. Straatman, J, Wielen, N, Nieuwenhuijzen, Gap, Rosman, C, Roig, J, Scheepers, Jjg, et.al. Techniques and short-term outcomes for total minimally invasive Ivor Lewis esophageal resection in distal esophageal and gastroesophageal junction cancers: pooled data from six European centers, Surgical endoscopy and other interventional techniques, 2017. 31(1): p. 119-126., https://pubmed.ncbi.nlm.nih.gov/27129563/
386. Seesing, M. F. J., Gisbertz, S. S., Goense, L., van Hillegersberg, R., Kroon, H. M., Lagarde, S. M., et.al. A Propensity Score Matched Analysis of Open Versus Minimally Invasive Transthoracic Esophagectomy in the Netherlands, Ann Surg, 2017. 266(5): p. 839-846., https://www.ncbi.nlm.nih.gov/pubmed/28796016
387. Schmidt, H. M., Gisbertz, S. S., Moons, J., Rouvelas, I., Kauppi, J., Brown, A., et.al. Defining Benchmarks for Transthoracic Esophagectomy: A Multicenter Analysis of Total Minimally Invasive Esophagectomy in Low Risk Patients, Ann Surg, 2017. 266(5): p. 814-821., https://www.ncbi.nlm.nih.gov/pubmed/28796646
388. Low, D. E., Alderson, D., Cecconello, I., Chang, A. C., Darling, G. E., D'Journo, X. B., et.al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG), Ann Surg, 2015., https://pubmed.ncbi.nlm.nih.gov/25607756/
389. Erhunmwunsee, L., Englum, B. R., Onaitis, M. W., D'Amico, T. A., Berry, M. F., Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions, Ann Surg Oncol, 2015. 22(3): p. 1020-5., https://pubmed.ncbi.nlm.nih.gov/25234017/
390. Shimoji, H., Karimata, H., Nagahama, M., Nishimaki, T., Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study, World J Surg, 2013. 37(9): p. 2180-8., https://pubmed.ncbi.nlm.nih.gov/23649529/
391. Al-Batran, SE, Homann, N, Pauligk, C, Illerhaus, G, Martens, UM, Stoehlmacher, J, et.al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial., JAMA Oncol, 2017. 3 (9)(9): p. 1237-1244., https://pubmed.ncbi.nlm.nih.gov/28448662/
392. Al-Batran, SE, Goetze, TO, Mueller, DW, Vogel, A, Winkler, M, Lorenzen, S, et.al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI., BMC Cancer, 2017. 17 (1)(1): p. 893., https://pubmed.ncbi.nlm.nih.gov/29282088/
393. Jamel, S, Tukanova, K, Markar, S, Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review., World J Gastrointest Oncol, 2019. 11 (9)(9): p. 741-749., https://pubmed.ncbi.nlm.nih.gov/31558978/
394. Weimann, A., Braga, M., Harsanyi, L., Laviano, A., Ljungqvist, O., Soeters, P., et.al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation, Clin Nutr, 2006. 25(2): p. 224-44., https://pubmed.ncbi.nlm.nih.gov/16698152/
395. Weimann, A, Breitenstein S, Breuer JP, et al., S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin: Klinische Ernährung in der Chirurgie., Aktuell Ernährungsmedizin, 2013. 38: p. e155-e197.
396. Kondrup, J., Allison, S. P., Elia, M., Vellas, B., Plauth, M., ESPEN guidelines for nutrition screening 2002, Clin Nutr, 2003. 22(4): p. 415-21., https://pubmed.ncbi.nlm.nih.gov/12880610/
397. Schwegler, I., von Holzen, A., Gutzwiller, J. P., Schlumpf, R., Muhlebach, S., Stanga, Z., Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer, Br J Surg, 2010. 97(1): p. 92-7., https://pubmed.ncbi.nlm.nih.gov/20013933/
398. Sorensen, J., Kondrup, J., Prokopowicz, J., Schiesser, M., Krahenbuhl, L., Meier, R., et.al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome, Clin Nutr, 2008. 27(3): p. 340-9., https://pubmed.ncbi.nlm.nih.gov/18504063/
399. Kuppinger, D., Hartl, W. H., Bertok, M., Hoffmann, J. M., Cederbaum, J., Kuchenhoff, H., et.al. Nutritional screening for risk prediction in patients scheduled for abdominal operations, Br J Surg, 2012. 99(5): p. 728-37., https://pubmed.ncbi.nlm.nih.gov/22362084/
400. Khuri, S. F., Daley, J., Henderson, W., Hur, K., Gibbs, J. O., Barbour, G., et.al. Risk adjustment of the postoperative mortality rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study, J Am Coll Surg, 1997. 185(4): p. 315-27., https://pubmed.ncbi.nlm.nih.gov/9328380/
401. Hennessey, D. B., Burke, J. P., Ni-Dhonochu, T., Shields, C., Winter, D. C., Mealy, K., Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study, Ann Surg, 2010. 252(2): p. 325-9., https://pubmed.ncbi.nlm.nih.gov/20647925/
402. Evans, DC, Corkins, MR, Malone, A, Miller, S, Mogensen, KM, Guenter, P, et.al. The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper., Nutr Clin Pract, 2021. 36 (1)(1): p. 22-28., https://pubmed.ncbi.nlm.nih.gov/33125793/
403. Deftereos, I, Kiss, N, Isenring, E, Carter, VM, Yeung, JM, A systematic review of the effect of preoperative nutrition support on nutritional status and treatment outcomes in upper gastrointestinal cancer resection., Eur J Surg Oncol, 2020. 46 (8)(8): p. 1423-1434., https://pubmed.ncbi.nlm.nih.gov/32336624/
404. Ligthart-Melis, G. C., Weijs, P. J., te Boveldt, N. D., Buskermolen, S., Earthman, C. P., Verheul, H. M., et.al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer, Dis Esophagus, 2013. 26(6): p. 587-93., https://pubmed.ncbi.nlm.nih.gov/23237356/
405. Ellrichmann, M., Sergeev, P., Bethge, J., Arlt, A., Topalidis, T., Ambrosch, P., et.al. Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers, Endoscopy, 2013. 45(7): p. 526-31., https://pubmed.ncbi.nlm.nih.gov/23780843/
406. Bozzetti, F., Gavazzi, C., Miceli, R., Rossi, N., Mariani, L., Cozzaglio, L., et.al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial, JPEN J Parenter Enteral Nutr, 2000. 24(1): p. 7-14., https://pubmed.ncbi.nlm.nih.gov/10638466/
407. Burden, S., Todd, C., Hill, J., Lal, S., Pre-operative nutrition support in patients undergoing gastrointestinal surgery, Cochrane Database Syst Rev, 2012. 11: p. Cd008879., https://pubmed.ncbi.nlm.nih.gov/23152265/
408. Hill, G. L., Impact of nutritional support on the clinical outcome of the surgical patient, Clin Nutr, 1994. 13(6): p. 331-40., https://pubmed.ncbi.nlm.nih.gov/16843410/
409. Jie, B., Jiang, Z. M., Nolan, M. T., Zhu, S. N., Yu, K., Kondrup, J., Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk, Nutrition, 2012. 28(10): p. 1022-7., https://pubmed.ncbi.nlm.nih.gov/22673593/
410. Osland, E., Hossain, M. B., Khan, S., Memon, M. A., Effect of timing of pharmaconutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta-analysis, JPEN J Parenter Enteral Nutr, 2014. 38(1): p. 53-69., https://pubmed.ncbi.nlm.nih.gov/23411423/
411. Mabvuure, N. T., Roman, A., Khan, O. A., Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer, Int J Surg, 2013. 11(2): p. 122-7., https://pubmed.ncbi.nlm.nih.gov/23274278/
412. Adiamah, A., Skorepa, P., Weimann, A., Lobo, D. N., The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis, Ann Surg, 2019. 270(2): p. 247-256., https://www.ncbi.nlm.nih.gov/pubmed/30817349
413. Daniels, SL, Lee, MJ, George, J, Kerr, K, Moug, S, Wilson, TR, et.al. Prehabilitation in elective abdominal cancer surgery in older patients: systematic review and meta-analysis., BJS Open, 2020. ():, https://pubmed.ncbi.nlm.nih.gov/32959532/
414. Perioperative Total Parenteral Nutrition in Surgical Patients, New England Journal of Medicine, 1991. 325(8): p. 525-532.
415. Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hubner, M., Klek, S., et.al. ESPEN guideline: Clinical nutrition in surgery, Clin Nutr, 2017. 36(3): p. 623-650., https://www.ncbi.nlm.nih.gov/pubmed/28385477
416. Weimann, A, Braga, M, Carli, F, Higashiguchi, T, Hübner, M, Klek, S, et.al. ESPEN practical guideline: Clinical nutrition in surgery., Clin Nutr, 2021. 40 (7)(7): p. 4745-4761., https://pubmed.ncbi.nlm.nih.gov/34242915/
417. Weimann, Arved, Breitenstein, Stefan, Gabor, Sabine, Holland-Cunz, Stefan, Kemen, Matthias, Längle, Friedrich, et.al. S3-Leitlinie Klinische Ernährung in der Chirurgie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) e. V, in Zusammenarbeit mit dem Arbeitskreis Klinische Ernährung (AKE), der Gesellschaft für Klinische Ernährung der Schweiz (GESKES) und den Fachgesellschaften Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI) e. V., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV) e. V., Deutsche Gesellschaft für Chirurgie (DGCH) e. V., 2023. 48(04): p. 237-290., http://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2104-9792
418. Andersen, H. K., Lewis, S. J., Thomas, S., Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications, Cochrane Database Syst Rev, 2006. p. Cd004080., https://pubmed.ncbi.nlm.nih.gov/17054196/
419. Lewis, S. J., Andersen, H. K., Thomas, S., Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis, J Gastrointest Surg, 2009. 13(3): p. 569-75., https://pubmed.ncbi.nlm.nih.gov/18629592/
420. Osland, E., Yunus, R. M., Khan, S., Memon, M. A., Early versus traditional postoperative feeding in patients undergoing resectional gastrointestinal surgery: a meta-analysis, JPEN J Parenter Enteral Nutr, 2011. 35(4): p. 473-87., https://pubmed.ncbi.nlm.nih.gov/21628607/
421. Berkelmans, G. H. K., Fransen, L. F. C., Dolmans-Zwartjes, A. C. P., Kouwenhoven, E. A., van Det, M. J., Nilsson, M., et.al. Direct Oral Feeding Following Minimally Invasive Esophagectomy (NUTRIENT II trial): An International, Multicenter, Open-label Randomized Controlled Trial, Ann Surg, 2020. 271(1): p. 41-47., https://www.ncbi.nlm.nih.gov/pubmed/31090563
422. Sica, G. S., Sujendran, V., Wheeler, J., Soin, B., Maynard, N., Needle catheter jejunostomy at esophagectomy for cancer, J Surg Oncol, 2005. 91(4): p. 276-9., https://pubmed.ncbi.nlm.nih.gov/16121345/
423. Han-Geurts, I. J., Hop, W. C., Verhoef, C., Tran, K. T., Tilanus, H. W., Randomized clinical trial comparing feeding jejunostomy with nasoduodenal tube placement in patients undergoing oesophagectomy, Br J Surg, 2007. 94(1): p. 31-5., https://pubmed.ncbi.nlm.nih.gov/17117432/
424. Gerritsen, A., Besselink, M. G., Cieslak, K. P., Vriens, M. R., Steenhagen, E., van Hillegersberg, R., et.al. Efficacy and complications of nasojejunal, jejunostomy and parenteral feeding after pancreaticoduodenectomy, J Gastrointest Surg, 2012. 16(6): p. 1144-51., https://pubmed.ncbi.nlm.nih.gov/22528573/
425. Markides, G. A., Alkhaffaf, B., Vickers, J., Nutritional access routes following oesophagectomy--a systematic review, Eur J Clin Nutr, 2011. 65(5): p. 565-73., https://pubmed.ncbi.nlm.nih.gov/21407246/
426. O'Farrell, N. J., Donohoe, C. L., Muldoon, C., Costelloe, J. M., King, S., Ravi, N., et.al. Lack of independent significance of a close (<1 mm) circumferential resection margin involvement in esophageal and junctional cancer, Ann Surg Oncol, 2013. 20(8): p. 2727-33., https://pubmed.ncbi.nlm.nih.gov/23463085/
427. Theologou, T., Diab, M., Kyaw, P. A., Gosney, J. R., McShane, J., Howes, N., et.al. The impact of positive circumferential margin on survival following oesophagectomy using the new 7th TNM classification, Eur J Cardiothorac Surg, 2013. 44(5): p. 855-9., https://pubmed.ncbi.nlm.nih.gov/23650023/
428. Fok, M., Sham, J. S., Choy, D., Cheng, S. W., Wong, J., Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study, Surgery, 1993. 113(2): p. 138-47., https://pubmed.ncbi.nlm.nih.gov/8430362/
429. Teniere, P., Hay, J. M., Fingerhut, A., Fagniez, P. L., Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research, Surg Gynecol Obstet, 1991. 173(2): p. 123-30., https://pubmed.ncbi.nlm.nih.gov/1925862/
430. Bao, Y., Liu, S., Zhou, Q., Cai, P., Anfossi, S., Li, Q., et.al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern, Radiat Oncol, 2013. 8: p. 241., https://pubmed.ncbi.nlm.nih.gov/24139225/
431. Fakhrian, K., Gamisch, N., Schuster, T., Thamm, R., Molls, M., Geinitz, H., Salvage radiotherapy in patients with recurrent esophageal carcinoma, Strahlenther Onkol, 2012. 188(2): p. 136-42., https://pubmed.ncbi.nlm.nih.gov/22218502/
432. Jingu, K., Matsushita, H., Takeda, K., Umezawa, R., Takahashi, C., Sugawara, T., et.al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study, BMC Cancer, 2012. 12: p. 542., https://pubmed.ncbi.nlm.nih.gov/23171077/
433. Ma, D. Y., Tan, B. X., Liu, M., Li, X. F., Zhou, Y. Q., Lu, Y., Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study, Radiat Oncol, 2014. 9: p. 28., https://pubmed.ncbi.nlm.nih.gov/24438695/
434. Oppedijk, V., van der Gaast, A., van Lanschot, J. J., van Hagen, P., van Os, R., van Rij, C. M., et.al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials, J Clin Oncol, 2014. 32(5): p. 385-91., https://pubmed.ncbi.nlm.nih.gov/24419108/
435. Sudo, K., Taketa, T., Correa, A. M., Campagna, M. C., Wadhwa, R., Blum, M. A., et.al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies, J Clin Oncol, 2013. 31(34): p. 4306-10., https://pubmed.ncbi.nlm.nih.gov/24145339/
436. Tukanova, KH, Chidambaram, S, Guidozzi, N, Hanna, GB, McGregor, AH, Markar, SR, Physiotherapy Regimens in Esophagectomy and Gastrectomy: a Systematic Review and Meta-Analysis., Ann Surg Oncol, 2022. 29 (5)(5): p. 3148-3167., https://pubmed.ncbi.nlm.nih.gov/34961901/
437. Arnott, S. J., Duncan, W., Gignoux, M., Hansen, H. S., Launois, B., Nygaard, K., et.al. Preoperative radiotherapy for esophageal carcinoma, Cochrane Database Syst Rev, 2005. p. Cd001799., https://pubmed.ncbi.nlm.nih.gov/16235286/
438. Schwer, A. L., Ballonoff, A., McCammon, R., Rusthoven, K., D'Agostino, R. B., Jr., Schefter, T. E., Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study, Int J Radiat Oncol Biol Phys, 2009. 73(2): p. 449-55., https://pubmed.ncbi.nlm.nih.gov/18538500/
439. Malthaner, R. A., Wong, R. K., Rumble, R. B., Zuraw, L., Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis, BMC.Med, 2004. 2: p. 35., https://pubmed.ncbi.nlm.nih.gov/15447788/
440. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial, Lancet, 2002. 359(9319): p. 1727-33.
441. Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., Langley, R. E., Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer, J Clin.Oncol., 2009. 27(30): p. 5062-5067., https://pubmed.ncbi.nlm.nih.gov/19770374/
442. Boonstra, J. J., Kok, T. C., Wijnhoven, B. P., van, Heijl M., van Berge Henegouwen, M. I., ten Kate, F. J., et.al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial, BMC.Cancer, 2011. 11: p. 181., https://pubmed.ncbi.nlm.nih.gov/21595951/
443. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., van de Velde, C. J., Nicolson, M., et.al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N.Engl.J Med, 2006. 355(1): p. 11-20., https://pubmed.ncbi.nlm.nih.gov/16822992/
444. Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., et.al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer, N.Engl.J Med, 1998. 339(27): p. 1979-1984., https://pubmed.ncbi.nlm.nih.gov/9869669/
445. Law, S., Fok, M., Chow, S., Chu, K. M., Wong, J., Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial, J Thorac.Cardiovasc.Surg., 1997. 114(2): p. 210-217., https://pubmed.ncbi.nlm.nih.gov/9270638/
446. Moehler, M., Al-Batran, S. E., Andus, T., Anthuber, M., Arends, J., Arnold, D., et.al. S3-Leitlinie „Magenkarzinom” -, Z Gastroenterol, 2011. 49(04): p. 461-531.
447. Ychou, M., Boige, V., Pignon, J. P., Conroy, T., Bouche, O., Lebreton, G., et.al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin.Oncol., 2011. 29(13): p. 1715-1721., https://pubmed.ncbi.nlm.nih.gov/21444866/
448. P., van Hagen, Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., et.al. Preoperative chemoradiotherapy for esophageal or junctional cancer, N.Engl.J Med, 2012. 366(22): p. 2074-2084., https://pubmed.ncbi.nlm.nih.gov/22646630/
449. Al-Batran, Salah-Eddin, Homann, Nils, Schmalenberg, Harald, Kopp, Hans-Georg, Haag, Georg Martin, Luley, Kim Barbara, et.al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial, Journal of Clinical Oncology, 2017. 35(15_suppl): p. 4004-4004., http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4004
450. Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., et.al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol., 2011. 12(7): p. 681-692., https://pubmed.ncbi.nlm.nih.gov/21684205/
451. Markar, S. R., Gronnier, C., Pasquer, A., Duhamel, A., Beal, H., Thereaux, J., et.al. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study, Eur J Cancer, 2016. 56: p. 59-68., https://pubmed.ncbi.nlm.nih.gov/26808298/
452. Speicher, P. J., Ganapathi, A. M., Englum, B. R., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., et.al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer, J Thorac Oncol, 2014. 9(8): p. 1195-201., https://pubmed.ncbi.nlm.nih.gov/25157773/
453. Crabtree, T. D., Kosinski, A. S., Puri, V., Burfeind, W., Bharat, A., Patterson, G. A., et.al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database, Ann Thorac Surg, 2013. 96(2): p. 382-90., https://pubmed.ncbi.nlm.nih.gov/23731608/
454. Wolfson, P, Ho, KMA, Bassett, P, Haidry, R, Olivo, A, Lovat, L, et.al. Accuracy of clinical staging for T2N0 oesophageal cancer: systematic review and meta-analysis., Dis Esophagus, 2021. 34 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/33618359/
455. Thuss-Patience, P., Vecchione, L., Keilholz, U., Should cT2 esophageal cancer get neoadjuvant treatment before surgery?, J Thorac Dis, 2017. 9(9): p. 2819-2823., https://pubmed.ncbi.nlm.nih.gov/29221247/
456. Cunningham, D., Allum, W., Weeden, S., Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial of the UK NCRI Upper GI Clinical Studies Group (the MAGIC trial, ISRCTN 93793971) [abstract], European.journal of cancer, 2003. 1: p. S18.
457. Clark, P. I., Medical Research Council (MRC) randomised phase III trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus, British.journal of cancer, 2000. 83: p. 1., http://www.nature.com/bjc/journal/v83/n1/pdf/6691309a.pdf
458. Moehler, M., Baltin, C. T., Ebert, M., Fischbach, W., Gockel, I., Grenacher, L., et.al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus, Gastric Cancer, 2014., https://pubmed.ncbi.nlm.nih.gov/25192931/
459. Al-Batran, SE, Homann, N, Pauligk, C, Goetze, TO, Meiler, J, Kasper, S, et.al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial., Lancet, 2019. 393 (10184)(10184): p. 1948-1957., https://pubmed.ncbi.nlm.nih.gov/30982686/
460. Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., et.al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 2004. 53(7): p. 925-30., https://pubmed.ncbi.nlm.nih.gov/15194636/
461. Bosset, J. F., Gignoux, M., Triboulet, J. P., Tiret, E., Mantion, G., Elias, D., et.al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N.Engl.J Med, 1997. 337(3): p. 161-167., https://pubmed.ncbi.nlm.nih.gov/9219702/
462. Lee, J. L., Park, S. I., Kim, S. B., Jung, H. Y., Lee, G. H., Kim, J. H., et.al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma, Ann.Oncol., 2004. 15(6): p. 947-954., https://pubmed.ncbi.nlm.nih.gov/15151953/
463. Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., et.al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781, J Clin Oncol, 2008. 26(7): p. 1086-92., https://pubmed.ncbi.nlm.nih.gov/18309943/
464. Montagnani, F., Fornaro, L., Frumento, P., Vivaldi, C., Falcone, A., Fioretto, L., Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis, Crit Rev Oncol Hematol, 2017. 114: p. 24-32., https://www.ncbi.nlm.nih.gov/pubmed/28477744
465. Burmeister, B. H., Smithers, B. M., Gebski, V., Fitzgerald, L., Simes, R. J., Devitt, P., et.al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial, Lancet Oncol, 2005. 6(9): p. 659-68., https://www.ncbi.nlm.nih.gov/pubmed/16129366
466. Cai, Z., Yin, Y., Zhao, Z., Xin, C., Cai, Z., Yin, Y., et.al. Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis, Front Pharmacol, 2018. 9: p. 872., https://www.ncbi.nlm.nih.gov/pubmed/30127746
467. Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., et.al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 2004. 53(7): p. 925-30., https://www.ncbi.nlm.nih.gov/pubmed/15194636
468. Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., Buchler, P., Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer, Br J Surg, 2011. 98(6): p. 768-83., https://www.ncbi.nlm.nih.gov/pubmed/21462364
469. Petrelli, F., Ghidini, M., Barni, S., Sgroi, G., Passalacqua, R., Tomasello, G., Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis, Gastric Cancer, 2019. 22(2): p. 245-254., https://www.ncbi.nlm.nih.gov/pubmed/30483986
470. Cheng, J., Cai, M., Shuai, X., Gao, J., Wang, G., Tao, K., Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis, Ther Adv Med Oncol, 2019. 11: p. 1758835919838963., https://www.ncbi.nlm.nih.gov/pubmed/31044021
471. Conroy, T., Galais, M. P., Raoul, J. L., Bouche, O., Gourgou-Bourgade, S., Douillard, J. Y., et.al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial, Lancet Oncol, 2014. 15(3): p. 305-14., https://pubmed.ncbi.nlm.nih.gov/24556041/
472. Herskovic, A., Martz, K., al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., et.al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 1992. 326(24): p. 1593-8., https://pubmed.ncbi.nlm.nih.gov/1584260/
473. van Hagen, P., Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., et.al. Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 2012. 366(22): p. 2074-84., https://www.ncbi.nlm.nih.gov/pubmed/22646630
474. Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., et.al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781, J Clin Oncol, 2008. 26(7): p. 1086-92., https://www.ncbi.nlm.nih.gov/pubmed/18309943
475. Urba, S. G., Orringer, M. B., Turrisi, A., Iannettoni, M., Forastiere, A., Strawderman, M., Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J Clin Oncol, 2001. 19(2): p. 305-13., https://www.ncbi.nlm.nih.gov/pubmed/11208820
476. Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., Hennessy, T. P., A comparison of multimodal therapy and surgery for esophageal adenocarcinoma, N Engl J Med, 1996. 335(7): p. 462-7., https://www.ncbi.nlm.nih.gov/pubmed/8672151
477. Zhao, Q, Li, Y, Wang, J, Zhang, J, Qiao, X, Tan, B, et.al. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction, American journal of the medical sciences, 2015. 349(6): p. 472-476., https://pubmed.ncbi.nlm.nih.gov/25996101/
478. Shapiro, J, Lanschot, Jj, Hulshof, Mc, Hagen, P, Berge, Henegouwen Mi, Wijnhoven, Bp, et.al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, The Lancet. Oncology, 2015. 16(9): p. 1090-8., https://pubmed.ncbi.nlm.nih.gov/26254683/
479. Lee, J. L., Park, S. I., Kim, S. B., Jung, H. Y., Lee, G. H., Kim, J. H., et.al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma, Ann Oncol, 2004. 15(6): p. 947-54., https://www.ncbi.nlm.nih.gov/pubmed/15151953
480. Cao, X. F., He, X. T., Ji, L., Xiao, J., Lv, J., Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma, Dis Esophagus, 2009. 22(6): p. 477-81., https://www.ncbi.nlm.nih.gov/pubmed/19703071
481. Lv, J., Cao, X. F., Zhu, B., Ji, L., Tao, L., Wang, D. D., Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma, World J Gastroenterol, 2010. 16(13): p. 1649-54., https://www.ncbi.nlm.nih.gov/pubmed/20355244
482. Yang, H., Liu, H., Chen, Y., Zhu, C., Fang, W., Yu, Z., et.al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial, J Clin Oncol, 2018. 36(27): p. 2796-2803., https://www.ncbi.nlm.nih.gov/pubmed/30089078
483. Burmeister, B. H., Smithers, B. M., Gebski, V., Fitzgerald, L., Simes, R. J., Devitt, P., et.al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial, Lancet Oncol., 2005. 6(9): p. 659-668., https://pubmed.ncbi.nlm.nih.gov/16129366/
484. Lv, J., Cao, X. F., Zhu, B., Ji, L., Tao, L., Wang, D. D., Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma, World J Gastroenterol., 2010. 16(13): p. 1649-1654., https://pubmed.ncbi.nlm.nih.gov/20355244/
485. Kumagai, K., Rouvelas, I., Tsai, J. A., Mariosa, D., Klevebro, F., Lindblad, M., et.al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers, Br J Surg, 2014. 101(4): p. 321-38., https://pubmed.ncbi.nlm.nih.gov/24493117/
486. Noordman, B. J., Verdam, M. G. E., Lagarde, S. M., Shapiro, J., Hulshof, Mccm, van Berge Henegouwen, M. I., et.al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial, Ann Oncol, 2018. 29(2): p. 445-451., https://www.ncbi.nlm.nih.gov/pubmed/29126244
487. Mariette, C., Dahan, L., Mornex, F., Maillard, E., Thomas, P. A., Meunier, B., et.al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901, J Clin Oncol, 2014. 32(23): p. 2416-22., https://www.ncbi.nlm.nih.gov/pubmed/24982463
488. Dresner, S. M., Lamb, P. J., Bennett, M. K., Hayes, N., Griffin, S. M., The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction, Surgery, 2001. 129(1): p. 103-9., https://www.ncbi.nlm.nih.gov/pubmed/11150040
489. Peyre, C. G., Hagen, J. A., DeMeester, S. R., Van Lanschot, J. J., Holscher, A., Law, S., et.al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes, Ann Surg, 2008. 248(6): p. 979-85., https://www.ncbi.nlm.nih.gov/pubmed/19092342
490. Mariette, C., Piessen, G., Lamblin, A., Mirabel, X., Adenis, A., Triboulet, J. P., Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma, Br J Surg, 2006. 93(9): p. 1077-83., https://www.ncbi.nlm.nih.gov/pubmed/16779882
491. Yang, H., Liu, H., Chen, Y., Zhu, C., Fang, W., Yu, Z., et.al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial, J Clin Oncol, 2018. 36(27): p. 2796-2803., https://www.ncbi.nlm.nih.gov/pubmed/30089078
492. Nagaraja, V., Cox, M. R., Eslick, G. D., Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis, J Gastrointest Oncol, 2014. 5(2): p. 119-26., https://www.ncbi.nlm.nih.gov/pubmed/24772340
493. Ahmed, O., Bolger, J. C., O'Neill, B., Robb, W. B., Use of esophageal stents to relieve dysphagia during neoadjuvant therapy prior to esophageal resection: a systematic review, Dis Esophagus, 2020. 33(1):, https://www.ncbi.nlm.nih.gov/pubmed/31828290
494. Helminen, O., Kauppila, J. H., Kyto, V., Gunn, J., Lagergren, J., Sihvo, E., Preoperative esophageal stenting and short-term outcomes of surgery for esophageal cancer in a population-based study from Finland and Sweden, Dis Esophagus, 2019. 32(11):, https://www.ncbi.nlm.nih.gov/pubmed/30855081
495. Reijm, A. N., Didden, P., Schelling, S. J. C., Siersema, P. D., Bruno, M. J., Spaander, M. C. W., Self-expandable metal stent placement for malignant esophageal strictures - changes in clinical outcomes over time, Endoscopy, 2019. 51(1): p. 18-29., https://www.ncbi.nlm.nih.gov/pubmed/29991071
496. Mariette, C., Gronnier, C., Duhamel, A., Mabrut, J. Y., Bail, J. P., Carrere, N., et.al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes, J Am Coll Surg, 2015. 220(3): p. 287-96., https://pubmed.ncbi.nlm.nih.gov/25617915/
497. Tham, J. E., Tharian, B., Allen, P. B., Spence, G., Tham, T. C., Oesophageal Stents for Potentially Curable Oesophageal Cancer - A Bridge to Surgery?, Ulster Med J, 2019. 88(1): p. 10-14., https://www.ncbi.nlm.nih.gov/pubmed/30675071
498. Spaander, M. C., Baron, T. H., Siersema, P. D., Fuccio, L., Schumacher, B., Escorsell, A., et.al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline, Endoscopy, 2016. 48(10): p. 939-48., https://www.ncbi.nlm.nih.gov/pubmed/27626318
499. Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H. J., Riera-Knorrenschild, J., et.al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction, J Clin Oncol, 2009. 27(6): p. 851-6., https://pubmed.ncbi.nlm.nih.gov/19139439/
500. Lordick, F., Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography, Recent Results Cancer Res, 2012. 196: p. 201-11., https://pubmed.ncbi.nlm.nih.gov/23129376/
501. Weber, W. A., Ott, K., Becker, K., Dittler, H. J., Helmberger, H., Avril, N. E., et.al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 2001. 19(12): p. 3058-65., https://pubmed.ncbi.nlm.nih.gov/11408502/
502. Ott, K., Weber, W. A., Lordick, F., Becker, K., Busch, R., Herrmann, K., et.al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction, J Clin Oncol, 2006. 24(29): p. 4692-8., https://pubmed.ncbi.nlm.nih.gov/16966684/
503. Ilson, D. H., Cancer of the gastroesophageal junction: combined modality therapy, Surg.Oncol.Clin.N.Am., 2006. 15(4): p. 803-824., https://pubmed.ncbi.nlm.nih.gov/17030275/
504. Wieder, H. A., Beer, A. J., Lordick, F., Ott, K., Fischer, M., Rummeny, E. J., et.al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction, J Nucl Med, 2005. 46(12): p. 2029-34., https://pubmed.ncbi.nlm.nih.gov/16330567/
505. Lordick, F., Ott, K., Krause, B. J., Weber, W. A., Becker, K., Stein, H. J., et.al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial, Lancet Oncol, 2007. 8(9): p. 797-805., https://pubmed.ncbi.nlm.nih.gov/17693134/
506. zum Buschenfelde, C. M., Herrmann, K., Schuster, T., Geinitz, H., Langer, R., Becker, K., et.al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial, J Nucl Med, 2011. 52(8): p. 1189-96., https://pubmed.ncbi.nlm.nih.gov/21764790/
507. Barbour, AP, Walpole, ET, Mai, GT, Barnes, EH, Watson, DI, Ackland, SP, et.al. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial., Ann Oncol, 2020. 31 (2)(2): p. 236-245., https://pubmed.ncbi.nlm.nih.gov/31959340/
508. Goodman, KA, Ou, FS, Hall, NC, Bekaii-Saab, T, Fruth, B, Twohy, E, et.al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial., J Clin Oncol, 2021. 39 (25)(25): p. 2803-2815., https://pubmed.ncbi.nlm.nih.gov/34077237/
509. Gillham, C. M., Lucey, J. A., Keogan, M., Duffy, G. J., Malik, V., Raouf, A. A., et.al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response, Br J Cancer, 2006. 95(9): p. 1174-9., https://pubmed.ncbi.nlm.nih.gov/17024121/
510. Klaeser, B., Nitzsche, E., Schuller, J. C., Koberle, D., Widmer, L., Balmer-Majno, S., et.al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02), Onkologie, 2009. 32(12): p. 724-30., https://pubmed.ncbi.nlm.nih.gov/20016233/
511. Malik, V., Lucey, J. A., Duffy, G. J., Wilson, L., McNamara, L., Keogan, M., et.al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus, J Nucl Med, 2010. 51(12): p. 1863-9., https://pubmed.ncbi.nlm.nih.gov/21078796/
512. van Heijl, M., Omloo, J. M., van Berge Henegouwen, M. I., Hoekstra, O. S., Boellaard, R., Bossuyt, P. M., et.al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer, Ann Surg, 2011. 253(1): p. 56-63., https://pubmed.ncbi.nlm.nih.gov/21233607/
513. al-Sarraf, M., Martz, K., Herskovic, A., Leichman, L., Brindle, J. S., Vaitkevicius, V. K., et.al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study, J Clin Oncol, 1997. 15(1): p. 277-84., https://pubmed.ncbi.nlm.nih.gov/8996153/
514. Crehange, G., Maingon, P., Peignaux, K., N'Guyen T, D., Mirabel, X., Marchal, C., et.al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102, J Clin Oncol, 2007. 25(31): p. 4895-901., https://pubmed.ncbi.nlm.nih.gov/17971585/
515. Karran, A., Blake, P., Chan, D., Reid, T. D., Davies, I. L., Kelly, M., et.al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy, Br J Surg, 2014. 101(5): p. 502-10., https://pubmed.ncbi.nlm.nih.gov/24615406/
516. Kato, H., Sato, A., Fukuda, H., Kagami, Y., Udagawa, H., Togo, A., et.al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708), Jpn J Clin Oncol, 2009. 39(10): p. 638-43., https://pubmed.ncbi.nlm.nih.gov/19549720/
517. Kawaguchi, Y., Nishiyama, K., Miyagi, K., Suzuki, O., Ito, Y., Nakamura, S., Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer, Jpn J Clin Oncol, 2011. 41(8): p. 1007-12., https://pubmed.ncbi.nlm.nih.gov/21665908/
518. Kuwano, Hiroyuki, Nishimura, Yasumasa, Ohtsu, Atsushi, Kato, Hiroyuki, Kitagawa, Yuko, Tamai, Setsuo, et.al. Guidelines for diagnosis and treatment of carcinoma of the esophagus, Esophagus, 2008. 5(3): p. 117-132., http://dx.doi.org/10.1007/s10388-008-0158-8
519. Wong, R., Malthaner, R., Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus, Cochrane Database Syst Rev, 2006. p. Cd002092., https://pubmed.ncbi.nlm.nih.gov/16437440/
520. Yamada, K., Murakami, M., Okamoto, Y., Okuno, Y., Nakajima, T., Kusumi, F., et.al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma, Int J Radiat Oncol Biol Phys, 2006. 64(4): p. 1106-11., https://pubmed.ncbi.nlm.nih.gov/16504758/
521. Chang, D. T., Chapman, C., Shen, J., Su, Z., Koong, A. C., Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis, Am.J Clin.Oncol., 2009. 32(4): p. 405-410., https://pubmed.ncbi.nlm.nih.gov/19415029/
522. Semenkovich, T. R., Meyers, B. F., Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation, Ann Transl Med, 2018. 6(4): p. 81., https://www.ncbi.nlm.nih.gov/pubmed/29666804
523. Wang, J., Qin, J., Jing, S., Liu, Q., Cheng, Y., Wang, Y., et.al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis, Thorac Cancer, 2018. 9(12): p. 1638-1647., https://www.ncbi.nlm.nih.gov/pubmed/30277016
524. Markar, S, Gronnier, C, Duhamel, A, Pasquer, A, Théreaux, J, du Rieu, MC, et.al. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?, J Clin Oncol, 2015. 33 (33)(33): p. 3866-73., https://pubmed.ncbi.nlm.nih.gov/26195702/
525. Gkika, E., Gauler, T., Eberhardt, W., Stahl, M., Stuschke, M., Pottgen, C., Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus, Dis Esophagus, 2014. 27(7): p. 678-84., https://pubmed.ncbi.nlm.nih.gov/24147973/
526. Grass, G. D., Cooper, S. L., Armeson, K., Garrett-Mayer, E., Sharma, A., Cervical esophageal cancer: A population-based study, Head Neck, 2014., https://pubmed.ncbi.nlm.nih.gov/24616217/
527. Burmeister, B. H., Dickie, G., Smithers, B. M., Hodge, R., Morton, K., Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy, Arch Otolaryngol Head Neck Surg, 2000. 126(2): p. 205-8., https://pubmed.ncbi.nlm.nih.gov/10680872/
528. Ajani, J. A., Barthel, J. S., Bentrem, D. J., D'Amico, T. A., Das, P., Denlinger, C. S., et.al. Esophageal and esophagogastric junction cancers, J Natl.Compr.Canc.Netw., 2011. 9(8): p. 830-887., https://pubmed.ncbi.nlm.nih.gov/21900218/
529. Gao, XS, Treatment guideline of radiotherapy for Chinese esophageal carcinoma (draft), Chin J Cancer, 2010. 29(10): p. 855-9., https://pubmed.ncbi.nlm.nih.gov/20868554/
530. Fenkell, L., Kaminsky, I., Breen, S., Huang, S., Van Prooijen, M., Ringash, J., Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus, Radiother Oncol, 2008. 89(3): p. 287-91., https://pubmed.ncbi.nlm.nih.gov/18789828/
531. Ma, J. B., Song, Y. P., Yu, J. M., Zhou, W., Cheng, E. C., Zhang, X. Q., et.al. Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer, Onkologie, 2011. 34(11): p. 599-604., https://pubmed.ncbi.nlm.nih.gov/22104156/
532. Tai, P., Van Dyk, J., Battista, J., Yu, E., Stitt, L., Tonita, J., et.al. Improving the consistency in cervical esophageal target volume definition by special training, Int J Radiat Oncol Biol Phys, 2002. 53(3): p. 766-74., https://pubmed.ncbi.nlm.nih.gov/12062623/
533. Ott, K., Lordick, F., Molls, M., Bartels, H., Biemer, E., Siewert, J. R., Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus, Br J Surg, 2009. 96(3): p. 258-66., https://pubmed.ncbi.nlm.nih.gov/19224522/
534. Panhofer, P., Springer, C., Izay, B., Grasl, M., Burian, M., Schoppmann, S. F., et.al. Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction, Langenbecks Arch Surg, 2013. 398(2): p. 221-30., https://pubmed.ncbi.nlm.nih.gov/22941244/
535. Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., Buchler, P., Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer, Br J Surg, 2011. 98(6): p. 768-83., https://pubmed.ncbi.nlm.nih.gov/21462364/
536. Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., et.al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 2007. 25(10): p. 1160-8., https://pubmed.ncbi.nlm.nih.gov/17401004/
537. Minsky, B. D., Pajak, T. F., Ginsberg, R. J., Pisansky, T. M., Martenson, J., Komaki, R., et.al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy, J Clin Oncol, 2002. 20(5): p. 1167-74., https://pubmed.ncbi.nlm.nih.gov/11870157/
538. Li, F., Ding, N., Zhao, Y., Yuan, L., Mao, Y., The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis, Int J Surg, 2018. 60: p. 88-100., https://www.ncbi.nlm.nih.gov/pubmed/30389537
539. Kamarajah, SK, Phillips, AW, Hanna, GB, Low, D, Markar, SR, Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study., Ann Surg, 2022. 275 (3)(3): p. 526-533., https://pubmed.ncbi.nlm.nih.gov/32865948/
540. Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., et.al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial, Lancet Oncol, 2013. 14(7): p. 627-37., https://pubmed.ncbi.nlm.nih.gov/23623280/
541. Meerten, EV, van Rij, C, Tesselaar, ME, Neelis, K, Richel, D, Hulshof, M, et.al. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: A phase II study, ASCO Annual Meeting Proceedings, 2010. 28: p. e14508., https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e14508
542. Suntharalingam, M., Winter, K., Ilson, D., Dicker, A. P., Kachnic, L. A., Konski, A. A., et.al. The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery, International Journal of Radiation Oncology • Biology • Physics, 2014. 90(1): p. S3., https://www.redjournal.org/article/S0360-3016(14)03348-3/fulltext
543. Stahl, M., Stuschke, M., Lehmann, N., Meyer, H. J., Walz, M. K., Seeber, S., et.al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus, J Clin Oncol, 2005. 23(10): p. 2310-7., https://pubmed.ncbi.nlm.nih.gov/15800321/
544. Hulshof, MCCM, Geijsen, ED, Rozema, T, Oppedijk, V, Buijsen, J, Neelis, KJ, et.al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)., J Clin Oncol, 2021. 39 (25)(25): p. 2816-2824., https://pubmed.ncbi.nlm.nih.gov/34101496/
545. Kole, T. P., Aghayere, O., Kwah, J., Yorke, E. D., Goodman, K. A., Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer, Int J Radiat Oncol Biol Phys, 2012. 83(5): p. 1580-6., https://pubmed.ncbi.nlm.nih.gov/22284687/
546. Lee, H. K., Vaporciyan, A. A., Cox, J. D., Tucker, S. L., Putnam, J. B., Jr., Ajani, J. A., et.al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters, Int J Radiat Oncol Biol Phys, 2003. 57(5): p. 1317-22., https://pubmed.ncbi.nlm.nih.gov/14630268/
547. Ruol, A., Rizzetto, C., Castoro, C., Cagol, M., Alfieri, R., Zanchettin, G., et.al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?, Ann Surg, 2010. 252(5): p. 788-96., https://pubmed.ncbi.nlm.nih.gov/21037434/
548. Kim, J. Y., Correa, A. M., Vaporciyan, A. A., Roth, J. A., Mehran, R. J., Walsh, G. L., et.al. Does the timing of esophagectomy after chemoradiation affect outcome?, Ann Thorac Surg, 2012. 93(1): p. 207-12; discussion 212-3., https://pubmed.ncbi.nlm.nih.gov/21962263/
549. Tachimori, Y., Role of salvage esophagectomy after definitive chemoradiotherapy, Gen Thorac Cardiovasc Surg, 2009. 57(2): p. 71-8., https://pubmed.ncbi.nlm.nih.gov/19214447/
550. Tomimaru, Y., Yano, M., Takachi, K., Miyashiro, I., Ishihara, R., Nishiyama, K., et.al. Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy, J Surg Oncol, 2006. 93(5): p. 422-8., https://pubmed.ncbi.nlm.nih.gov/16550581/
551. Faiz, Z., Dijksterhuis, W. P. M., Burgerhof, J. G. M., Muijs, C. T., Mul, V. E. M., Wijnhoven, B. P. L., et.al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy, Eur J Surg Oncol, 2019. 45(6): p. 931-940., https://www.ncbi.nlm.nih.gov/pubmed/30447937
552. Marks, J. L., Hofstetter, W., Correa, A. M., Mehran, R. J., Rice, D., Roth, J., et.al. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma, Ann Thorac Surg, 2012. 94(4): p. 1126-32; discussion 1132-3., https://pubmed.ncbi.nlm.nih.gov/22921233/
553. Taketa, T., Xiao, L., Sudo, K., Suzuki, A., Wadhwa, R., Blum, M. A., et.al. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation, Oncology, 2013. 85(2): p. 95-9., https://pubmed.ncbi.nlm.nih.gov/23860252/
554. Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., et.al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 2014. 383(9911): p. 31-9., https://pubmed.ncbi.nlm.nih.gov/24094768/
555. Ariga, H., Nemoto, K., Miyazaki, S., Yoshioka, T., Ogawa, Y., Sakayauchi, T., et.al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus, Int J Radiat Oncol Biol Phys, 2009. 75(2): p. 348-56., https://pubmed.ncbi.nlm.nih.gov/19735862/
556. Cohen, C., Tessier, W., Gronnier, C., Renaud, F., Pasquer, A., Thereaux, J., et.al. Salvage Surgery for Esophageal Cancer: How to Improve Outcomes?, Ann Surg Oncol, 2018. 25(5): p. 1277-1286., https://www.ncbi.nlm.nih.gov/pubmed/29417405
557. Safran, HP, Winter, K, Ilson, DH, Wigle, D, DiPetrillo, T, Haddock, MG, et.al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial., Lancet Oncol, 2022. 23 (2)(2): p. 259-269., https://pubmed.ncbi.nlm.nih.gov/35038433/
558. Zheng, B., Zheng, W., Zhu, Y., Lin, X. Y., Xu, B. H., Chen, C., Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis, Chin Med J (Engl.), 2013. 126(6): p. 1178-1182., https://pubmed.ncbi.nlm.nih.gov/23506601/
559. Thallinger, C. M., Kiesewetter, B., Raderer, M., Hejna, M., Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma, Anticancer Res, 2012. 32(11): p. 4609-4627., https://pubmed.ncbi.nlm.nih.gov/23155224/
560. Luo, H., Cui, Y. Y., Zhang, J. G., Sun, Y. N., Zheng, X. L., Yang, C. L., et.al. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma, Clin Transl Oncol, 2018. 20(7): p. 889-898., https://www.ncbi.nlm.nih.gov/pubmed/29143229
561. Kang, J., Chang, J. Y., Sun, X., Men, Y., Zeng, H., Hui, Z., Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients, J Cancer, 2018. 9(3): p. 584-593., https://www.ncbi.nlm.nih.gov/pubmed/29483964
562. Liu, T., Liu, W., Zhang, H., Ren, C., Chen, J., Dang, J., The role of postoperative radiotherapy for radically resected esophageal squamous cell carcinoma: a systemic review and meta-analysis, J Thorac Dis, 2018. 10(7): p. 4403-4412., https://www.ncbi.nlm.nih.gov/pubmed/30174889
563. Shah, M. A., Kennedy, E. B., Catenacci, D. V., Deighton, D. C., Goodman, K. A., Malhotra, N. K., et.al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline, J Clin Oncol, 2020. 38(23): p. 2677-2694., https://www.ncbi.nlm.nih.gov/pubmed/32568633
564. Rice, T. W., Rusch, V. W., Apperson-Hansen, C., Allen, M. S., Chen, L. Q., Hunter, J. G., et.al. Worldwide esophageal cancer collaboration, Dis Esophagus, 2009. 22(1): p. 1-8., https://www.ncbi.nlm.nih.gov/pubmed/19196264
565. Morimoto, J, Tanaka, H, Ohira, M, Kubo, N, Muguruma, K, Sakurai, K, et.al. The impact of the number of occult metastatic lymph nodes on postoperative relapse of resectable esophageal cancer., Dis Esophagus, 2014. 27 (1)(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/23480452/
566. Tan, Z., Ma, G., Yang, H., Zhang, L., Rong, T., Lin, P., Can lymph node ratio replace pn categories in the tumor-node-metastasis classification system for esophageal cancer?, J Thorac Oncol, 2014. 9(8): p. 1214-21., https://www.ncbi.nlm.nih.gov/pubmed/25157776
567. Wang, N., Jia, Y., Wang, J., Wang, X., Bao, C., Song, Q., et.al. Prognostic significance of lymph node ratio in esophageal cancer, Tumour Biol, 2015. 36(4): p. 2335-41., https://www.ncbi.nlm.nih.gov/pubmed/25412956
568. Malthaner, R. A., Wong, R. K., Rumble, R. B., Zuraw, L., Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based, Care, Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis, BMC Med, 2004. 2: p. 35., https://www.ncbi.nlm.nih.gov/pubmed/15447788
569. Liu, T., Liu, W., Zhang, H., Ren, C., Chen, J., Dang, J., The role of postoperative radiotherapy for radically resected esophageal squamous cell carcinoma: a systemic review and meta-analysis, J Thorac Dis, 2018. 10(7): p. 4403-4412., https://www.ncbi.nlm.nih.gov/pubmed/30174889
570. Zhang, X., Yang, X., Ni, J., Li, Y., Zou, L., Chu, L., et.al. Recommendation for the definition of postoperative radiotherapy target volume based on a pooled analysis of patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma, Radiat Oncol, 2018. 13(1): p. 255., https://www.ncbi.nlm.nih.gov/pubmed/30587211
571. Fok, M., Sham, J. S., Choy, D., Cheng, S. W., Wong, J., Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study, Surgery, 1993. 113(2): p. 138-47., https://www.ncbi.nlm.nih.gov/pubmed/8430362
572. Teniere, P., Hay, J. M., Fingerhut, A., Fagniez, P. L., Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research, Surg Gynecol Obstet, 1991. 173(2): p. 123-30., https://www.ncbi.nlm.nih.gov/pubmed/1925862
573. Deng, W., Yang, J., Ni, W., Li, C., Chang, X., Han, W., et.al. Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study, Oncologist, 2020. 25(4): p. e701-e708., https://www.ncbi.nlm.nih.gov/pubmed/32083766
574. Zhao, X. H., Wang, D., Wang, F., Zhu, S. C., Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis, Medicine (Baltimore), 2018. 97(47): p. e13168., https://www.ncbi.nlm.nih.gov/pubmed/30461614
575. Ni, W, Yu, S, Xiao, Z, Zhou, Z, Chen, D, Feng, Q, et.al. Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial., Oncologist, 2021. 26 (12)(12): p. e2151-e2160., https://pubmed.ncbi.nlm.nih.gov/34309117/
576. Ohri, N., Garg, M. K., Aparo, S., Kaubisch, A., Tome, W., Kennedy, T. J., et.al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis, Int J Radiat Oncol Biol Phys, 2013. 86(2): p. 330-5., https://pubmed.ncbi.nlm.nih.gov/23523184/
577. Bamias, A., Karina, M., Papakostas, P., Kostopoulos, I., Bobos, M., Vourli, G., et.al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer, Cancer Chemother Pharmacol, 2010. 65(6): p. 1009-21., https://pubmed.ncbi.nlm.nih.gov/20130877/
578. Lee, J., Lim, D. H., Kim, S., Park, S. H., Park, J. O., Park, Y. S., et.al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial, J Clin Oncol, 2012. 30(3): p. 268-73., https://www.ncbi.nlm.nih.gov/pubmed/22184384
579. Lee, J., Lim do, H., Kim, S., Park, S. H., Park, J. O., Park, Y. S., et.al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial, J Clin Oncol, 2012. 30(3): p. 268-73., https://pubmed.ncbi.nlm.nih.gov/22184384/
580. Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., et.al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 2001. 345(10): p. 725-30., https://pubmed.ncbi.nlm.nih.gov/11547741/
581. Kwon, H. C., Kim, M. C., Kim, K. H., Jang, J. S., Oh, S. Y., Kim, S. H., et.al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection, Asia Pac J Clin Oncol, 2010. 6(4): p. 278-85., https://pubmed.ncbi.nlm.nih.gov/21114777/
582. Fuchs, C. S., Niedzwiecki, D., Mamon, H. J., Tepper, J. E., Ye, X., Swanson, R. S., et.al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance), J Clin Oncol, 2017. 35(32): p. 3671-3677., https://www.ncbi.nlm.nih.gov/pubmed/28976791
583. Park, SH, Lim, DH, Sohn, TS, Lee, J, Zang, DY, Kim, ST, et.al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial, Ann Oncol, 2021. 32 (3)(3): p. 368-374., https://pubmed.ncbi.nlm.nih.gov/33278599/
584. Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J. P., et.al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, Jama, 2010. 303(17): p. 1729-37., https://pubmed.ncbi.nlm.nih.gov/20442389/
585. Bang, YJ, Kim, YW, Yang, HK, Chung, HC, Park, YK, Lee, KH, et.al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial., Lancet, 2012. 379 (9813)(9813): p. 315-21., https://pubmed.ncbi.nlm.nih.gov/22226517/
586. Kelly, RJ, Ajani, JA, Kuzdzal, J, Zander, T, Van Cutsem, E, Piessen, G, et.al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer., N Engl J Med, 2021. 384 (13)(13): p. 1191-1203., https://pubmed.ncbi.nlm.nih.gov/33789008/
587. Pape, Marieke, Vissers, Pauline A.J., Beerepoot, Laurens, Van Berge Henegouwen, Mark I., Lagarde, Sjoerd, Mook, Stella, et.al. Disease-free and overall survival in nonmetastatic esophageal or gastroesophageal junctional cancer after treatment with curative intent: A nationwide population-based study.Wolters Kluwer, Journal of Clinical Oncology, 2021. 39(3_suppl): p. 246 - 246., https://doi.org/10.1200/JCO.2021.39.3_suppl.246
588. Abate, E., DeMeester, S. R., Zehetner, J., Oezcelik, A., Ayazi, S., Costales, J., et.al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing, J Am Coll Surg, 2010. 210(4): p. 428-35., https://pubmed.ncbi.nlm.nih.gov/20347734/
589. Mantziari, S., Allemann, P., Dayer, A., Demartines, N., Schafer, M., [Gastroesophageal cancer: an update on diagnosis and treatment], Rev Med Suisse, 2014. 10(435): p. 1331-6., https://pubmed.ncbi.nlm.nih.gov/25051595/
590. Kroese, TE, van Laarhoven, HWM, Nilsson, M, Lordick, F, Guckenberger, M, Ruurda, JP, et.al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis., Eur J Cancer, 2022. 166 (): p. 254-269., https://pubmed.ncbi.nlm.nih.gov/35339868/
591. Bjerring, OS, Fristrup, CW, Pfeiffer, P, Lundell, L, Mortensen, MB, Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study)., Br J Surg, 2019. 106 (13)(13): p. 1761-1768., https://pubmed.ncbi.nlm.nih.gov/31595970/
592. Ouattara, M., D'Journo, X. B., Loundou, A., Trousse, D., Dahan, L., Doddoli, C., et.al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer, Eur J Cardiothorac Surg, 2012. 41(5): p. 1088-93., https://pubmed.ncbi.nlm.nih.gov/22334635/
593. Haverkort, E. B., Binnekade, J. M., de Haan, R. J., Busch, O. R., van Berge Henegouwen, M. I., Gouma, D. J., Suboptimal intake of nutrients after esophagectomy with gastric tube reconstruction, J Acad Nutr Diet, 2012. 112(7): p. 1080-7., https://pubmed.ncbi.nlm.nih.gov/22889637/
594. Koterazawa, Y, Oshikiri, T, Hasegawa, H, Yamamoto, M, Kanaji, S, Yamashita, K, et.al. Routine placement of feeding jejunostomy tube during esophagectomy increases postoperative complications and does not improve postoperative malnutrition., Dis Esophagus, 2020. 33 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/30997494/
595. Wobith, M, Wehle, L, Haberzettl, D, Acikgöz, A, Weimann, A, Needle Catheter Jejunostomy in Patients Undergoing Surgery for Upper Gastrointestinal and Pancreato-Biliary Cancer-Impact on Nutritional and Clinical Outcome in the Early and Late Postoperative Period., Nutrients, 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32854177/
596. Ryan, A. M., Rowley, S. P., Healy, L. A., Flood, P. M., Ravi, N., Reynolds, J. V., Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit, Clin Nutr, 2006. 25(3): p. 386-93., https://pubmed.ncbi.nlm.nih.gov/16697499/
597. Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hubner, M., Klek, S., et.al. ESPEN guideline: Clinical nutrition in surgery, Clin Nutr, 2017. 36(3): p. 623-650., https://www.ncbi.nlm.nih.gov/pubmed/28385477
598. Chen, X, Zhao, G, Zhu, L, Home enteral nutrition for postoperative elderly patients with esophageal cancer., Ann Palliat Med, 2021. 10 (1)(1): p. 278-284., https://pubmed.ncbi.nlm.nih.gov/33545764/
599. Xueting, H, Li, L, Meng, Y, Yuqing, C, Yutong, H, Lihong, Q, et.al. Home enteral nutrition and oral nutritional supplements in postoperative patients with upper gastrointestinal malignancy: A systematic review and meta-analysis., Clin Nutr, 2021. 40 (5)(5): p. 3082-3093., https://pubmed.ncbi.nlm.nih.gov/33279310/
600. Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Exercise interventions on health-related quality of life for people with cancer during active treatment, Cochrane Database Syst Rev, 2012. 8: p. Cd008465., https://pubmed.ncbi.nlm.nih.gov/22895974/
601. Bourke, L., Homer, K. E., Thaha, M. A., Steed, L., Rosario, D. J., Robb, K. A., et.al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review, Br J Cancer, 2014. 110(4): p. 831-41., https://pubmed.ncbi.nlm.nih.gov/24335923/
602. Rock, C. L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., et.al. Nutrition and physical activity guidelines for cancer survivors, CA Cancer J Clin, 2012. 62(4): p. 243-74., https://pubmed.ncbi.nlm.nih.gov/22539238/
603. Mishra, S. I., Scherer, R. W., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Gotay, C. C., et.al. Exercise interventions on health-related quality of life for cancer survivors, Cochrane Database Syst Rev, 2012. 8: p. Cd007566., https://pubmed.ncbi.nlm.nih.gov/22895961/
604. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/
605. Adler, K, Schlieper, D, Kindgen-Milles, D, Meier, S, Schwartz, J, van Caster, P, et.al. [Integration of palliative care into intensive care : Systematic review]., Anaesthesist, 2017. 66 (9)(9): p. 660-666., https://pubmed.ncbi.nlm.nih.gov/28589374/
606. Dalgaard, KM, Bergenholtz, H, Nielsen, ME, Timm, H, Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome., Palliat Support Care, 2014. 12 (6)(6): p. 495-513., https://pubmed.ncbi.nlm.nih.gov/24621947/
607. Davis, MP, Temel, JS, Balboni, T, Glare, P, A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses., Ann Palliat Med, 2015. 4 (3)(3): p. 99-121., https://pubmed.ncbi.nlm.nih.gov/26231807/
608. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis., BMJ, 2017. 357 (): p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/
609. Hui, D, Kim, YJ, Park, JC, Zhang, Y, Strasser, F, Cherny, N, et.al. Integration of oncology and palliative care: a systematic review., Oncologist, 2015. 20 (1)(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/25480826/
610. Tassinari, D, Drudi, F, Monterubbianesi, MC, Stocchi, L, Ferioli, I, Marzaloni, A, et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature., Rev Recent Clin Trials, 2016. 11 (1)(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/26464077/
611. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V. und Deutschen Krebshilfe, Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
612. Hui, D, Meng, YC, Bruera, S, Geng, Y, Hutchins, R, Mori, M, et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review., Oncologist, 2016. 21 (7)(7): p. 895-901., https://pubmed.ncbi.nlm.nih.gov/27185614/
613. Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., et.al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer, J Clin Oncol, 2002. 20(8): p. 1996-2004., https://pubmed.ncbi.nlm.nih.gov/11956258/
614. Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et.al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 2006. 24(31): p. 4991-7., https://pubmed.ncbi.nlm.nih.gov/17075117/
615. Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., et.al. Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 2008. 358(1): p. 36-46., https://pubmed.ncbi.nlm.nih.gov/18172173/
616. Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., et.al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer, J Clin Oncol, 1997. 15(1): p. 261-7., https://pubmed.ncbi.nlm.nih.gov/8996151/
617. Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., et.al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial, J Clin.Oncol., 2010. 28(9): p. 1547-1553., https://pubmed.ncbi.nlm.nih.gov/20159816/
618. Al-Batran, S. E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., et.al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin.Oncol., 2008. 26(9): p. 1435-1442., https://pubmed.ncbi.nlm.nih.gov/18349393/
619. Kang, Y. K., Kang, W. K., Shin, D. B., Chen, J., Xiong, J., Wang, J., et.al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 2009. 20(4): p. 666-73., https://pubmed.ncbi.nlm.nih.gov/19153121/
620. Okines, A. F., Norman, A. R., McCloud, P., Kang, Y. K., Cunningham, D., Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann.Oncol., 2009. 20(9): p. 1529-1534., https://pubmed.ncbi.nlm.nih.gov/19474114/
621. Janjigian, YY, Shitara, K, Moehler, M, Garrido, M, Salman, P, Shen, L, et.al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial., Lancet, 2021. 398 (10294)(10294): p. 27-40., https://pubmed.ncbi.nlm.nih.gov/34102137/
622. Sun, JM, Shen, L, Shah, MA, Enzinger, P, Adenis, A, Doi, T, et.al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study., Lancet, 2021. 398 (10302)(10302): p. 759-771., https://pubmed.ncbi.nlm.nih.gov/34454674/
623. Lutz, M. P., Wilke, H., Wagener, D. J., Vanhoefer, U., Jeziorski, K., Hegewisch-Becker, S., et.al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 2007. 25(18): p. 2580-5., https://pubmed.ncbi.nlm.nih.gov/17577037/
624. Al-Batran, S. E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., et.al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 2008. 19(11): p. 1882-7., https://pubmed.ncbi.nlm.nih.gov/18669868/
625. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagastric Junction Cancers. National Comprehensive Cancer Network., 2011.
626. Guimbaud, R, Louvet, C, Ries, P, Ychou, M, Maillard, E, André, T, et.al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study., J Clin Oncol, 2014. 32 (31)(31): p. 3520-6., https://pubmed.ncbi.nlm.nih.gov/25287828/
627. Shah, MA, Janjigian, YY, Stoller, R, Shibata, S, Kemeny, M, Krishnamurthi, S, et.al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium., J Clin Oncol, 2015. 33 (33)(33): p. 3874-9., https://pubmed.ncbi.nlm.nih.gov/26438119/
628. Xiang, X. J., Zhang, L., Qiu, F., Yu, F., Zhan, Z. Y., Feng, M., et.al. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer, Chemotherapy, 2012. 58(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/22310723/
629. Catalano, V., Bisonni, R., Graziano, F., Giordani, P., Alessandroni, P., Baldelli, A. M., et.al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases, Gastric Cancer, 2013. 16(3): p. 411-9., https://pubmed.ncbi.nlm.nih.gov/23065042/
630. Al-Batran, S. E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., et.al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+), Eur J Cancer, 2013. 49(4): p. 835-42., https://pubmed.ncbi.nlm.nih.gov/23063354/
631. Hall, P. S., Lord, S. R., Collinson, M., Marshall, H., Jones, M., Lowe, C., et.al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO), Br J Cancer, 2017. 116(4): p. 472-478., https://pubmed.ncbi.nlm.nih.gov/28095397/
632. Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., et.al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study, Lancet Oncol, 2018. 19(10): p. 1372-1384., https://www.ncbi.nlm.nih.gov/pubmed/30217672
633. Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., et.al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study, Lancet Oncol, 2017. 18(5): p. 640-653., https://pubmed.ncbi.nlm.nih.gov/28343975/
634. Doki, Y, Ajani, JA, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, et.al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma., N Engl J Med, 2022. 386 (5)(5): p. 449-462., https://pubmed.ncbi.nlm.nih.gov/35108470/
635. Luo, H, Lu, J, Bai, Y, Mao, T, Wang, J, Fan, Q, et.al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial., JAMA, 2021. 326 (10)(10): p. 916-925., https://pubmed.ncbi.nlm.nih.gov/34519801/
636. Grunberger, B., Raderer, M., Schmidinger, M., Hejna, M., Palliative chemotherapy for recurrent and metastatic esophageal cancer, Anticancer Res., 2007. 27(4C): p. 2705-2714., https://pubmed.ncbi.nlm.nih.gov/17695436/
637. NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network, 1999.
638. Noronha, Vanita, Patil, Vijay Maruti, Menon, Nandini Sharrel, Singh, Ajaykumar, Chopade, Sunil Ramdhan, Janu, Amit, et.al. Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer.Wolters Kluwer, Journal of Clinical Oncology, 2022. 40(16_suppl): p. 4065 - 4065., https://doi.org/10.1200/JCO.2022.40.16_suppl.4065
639. Yoon, H., Kato, K., Raymond, E., Hubner, R., Shu, Y., Pan, Y., et.al. LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC), Annals of Oncology, 2022. 33: p. S375., https://doi.org/10.1016/j.annonc.2022.04.439
640. Adam, R., Chiche, L., Aloia, T., Elias, D., Salmon, R., Rivoire, M., et.al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model, Ann Surg, 2006. 244(4): p. 524-35., https://pubmed.ncbi.nlm.nih.gov/16998361/
641. Shiono, S., Kawamura, M., Sato, T., Nakagawa, K., Nakajima, J., Yoshino, I., et.al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases, J Thorac Oncol, 2008. 3(9): p. 1046-9., https://pubmed.ncbi.nlm.nih.gov/18758309/
642. Ichikawa, H., Kosugi, S., Nakagawa, S., Kanda, T., Tsuchida, M., Koike, T., et.al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma, Surgery, 2011. 149(2): p. 164-70., https://pubmed.ncbi.nlm.nih.gov/20817205/
643. Ichida, H., Imamura, H., Yoshimoto, J., Sugo, H., Kajiyama, Y., Tsurumaru, M., et.al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma, World J Surg, 2013. 37(2): p. 398-407., https://pubmed.ncbi.nlm.nih.gov/23142988/
644. Miyata, H., Yamasaki, M., Takiguchi, S., Nakajima, K., Fujiwara, Y., Nishida, T., et.al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer, J Surg Oncol, 2009. 100(6): p. 442-6., https://pubmed.ncbi.nlm.nih.gov/19653262/
645. Morita, M., Kumashiro, R., Hisamatsu, Y., Nakanishi, R., Egashira, A., Saeki, H., et.al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy, J Gastroenterol, 2011. 46(11): p. 1284-91., https://pubmed.ncbi.nlm.nih.gov/21818602/
646. Schieman, C., Wigle, D. A., Deschamps, C., Nichols, F. C., 3rd, Cassivi, S. D., Shen, K. R., et.al. Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy, Ann Thorac Surg, 2013. 95(2): p. 459-63., https://pubmed.ncbi.nlm.nih.gov/23245442/
647. Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., et.al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 2011. 47(15): p. 2306-14., https://pubmed.ncbi.nlm.nih.gov/21742485/
648. Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., et.al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial, J Clin Oncol, 2013. 31(35): p. 4438-44., https://pubmed.ncbi.nlm.nih.gov/24190112/
649. Ford, H. E., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., et.al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 2014. 15(1): p. 78-86., https://pubmed.ncbi.nlm.nih.gov/24332238/
650. Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., et.al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 2014. 15(11): p. 1224-35., https://pubmed.ncbi.nlm.nih.gov/25240821/
651. Shitara, K, Doi, T, Dvorkin, M, Mansoor, W, Arkenau, HT, Prokharau, A, et.al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2018. 19 (11)(11): p. 1437-1448., https://pubmed.ncbi.nlm.nih.gov/30355453/
652. Fuchs, CS, Doi, T, Jang, RW, Muro, K, Satoh, T, Machado, M, et.al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial., JAMA Oncol, 2018. 4 (5)(5): p. e180013., https://pubmed.ncbi.nlm.nih.gov/29543932/
653. Shitara, K, Van Cutsem, E, Bang, YJ, Fuchs, C, Wyrwicz, L, Lee, KW, et.al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial., JAMA Oncol, 2020. 6 (10)(10): p. 1571-1580., https://pubmed.ncbi.nlm.nih.gov/32880601/
654. Shitara, K., Ozguroglu, M., Bang, Y. J., Di Bartolomeo, M., Mandala, M., Ryu, M. H., et.al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial, Lancet, 2018. 392(10142): p. 123-133., https://www.ncbi.nlm.nih.gov/pubmed/29880231
655. Fuchs, C. S., Niedzwiecki, D., Mamon, H. J., Tepper, J. E., Ye, X., Swanson, R. S., et.al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance), J Clin Oncol, 2017. 35(32): p. 3671-3677., https://www.ncbi.nlm.nih.gov/pubmed/28976791
656. Shitara, K, Bang, YJ, Iwasa, S, Sugimoto, N, Ryu, MH, Sakai, D, et.al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer., N Engl J Med, 2020. 382 (25)(25): p. 2419-2430., https://pubmed.ncbi.nlm.nih.gov/32469182/
657. Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., et.al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 2019. 20(11): p. 1506-1517., https://www.ncbi.nlm.nih.gov/pubmed/31582355
658. Huang, J, Xu, J, Chen, Y, Zhuang, W, Zhang, Y, Chen, Z, et.al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study., Lancet Oncol, 2020. 21 (6)(6): p. 832-842., https://pubmed.ncbi.nlm.nih.gov/32416073/
659. Shen, L, Kato, K, Kim, SB, Ajani, JA, Zhao, K, He, Z, et.al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study., J Clin Oncol, 2022. 40 (26)(26): p. 3065-3076., https://pubmed.ncbi.nlm.nih.gov/35442766/
660. Thallinger, C. M., Raderer, M., Hejna, M., Esophageal cancer: a critical evaluation of systemic second-line therapy, J Clin Oncol, 2011. 29(35): p. 4709-14., https://pubmed.ncbi.nlm.nih.gov/22067408/
661. Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., et.al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study, JAMA Oncol, 2019. 5(4): p. 546-550., https://www.ncbi.nlm.nih.gov/pubmed/30570649
662. Amdal, C. D., Jacobsen, A. B., Guren, M. G., Bjordal, K., Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review, Acta Oncol, 2013. 52(4): p. 679-90., https://pubmed.ncbi.nlm.nih.gov/23190360/
663. Javed, A., Pal, S., Dash, N. R., Ahuja, V., Mohanti, B. K., Vishnubhatla, S., et.al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial, J Gastrointest.Cancer, 2012. 43(1): p. 63-69., https://pubmed.ncbi.nlm.nih.gov/20835926/
664. Sgourakis, G., Gockel, I., Karaliotas, C., Moehler, M., Schimanski, C. C., Schmidberger, H., et.al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study, BMC.Cancer, 2012. 12: p. 70., https://pubmed.ncbi.nlm.nih.gov/22336151/
665. Amdal, C. D., Jacobsen, A. B., Sandstad, B., Warloe, T., Bjordal, K., Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial, Radiother Oncol, 2013. 107(3): p. 428-33., https://pubmed.ncbi.nlm.nih.gov/23647761/
666. Homs, M. Y., Steyerberg, E. W., Eijkenboom, W. M., Tilanus, H. W., Stalpers, L. J., Bartelsman, J. F., et.al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial, Lancet, 2004. 364(9444): p. 1497-1504., https://pubmed.ncbi.nlm.nih.gov/15500894/
667. Rosenblatt, E., Jones, G., Sur, R. K., Donde, B., Salvajoli, J. V., Ghosh-Laskar, S., et.al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency, Radiother.Oncol., 2010. 97(3): p. 488-494., https://pubmed.ncbi.nlm.nih.gov/20950882/
668. Sgourakis, G., Gockel, I., Radtke, A., Dedemadi, G., Goumas, K., Mylona, S., et.al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes, Dig.Dis.Sci, 2010. 55(11): p. 3018-3030., https://pubmed.ncbi.nlm.nih.gov/20440646/
669. Sabharwal, T., Hamady, M. S., Chui, S., Atkinson, S., Mason, R., Adam, A., A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma, Gut, 2003. 52(7): p. 922-926., https://pubmed.ncbi.nlm.nih.gov/12801944/
670. Shenfine, J., McNamee, P., Steen, N., Bond, J., Griffin, S. M., A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer, Health Technol Assess, 2005. 9(5): p. iii, 1-121., https://pubmed.ncbi.nlm.nih.gov/15717937/
671. Vakil, N., Morris, A. I., Marcon, N., Segalin, A., Peracchia, A., Bethge, N., et.al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction, Am J Gastroenterol, 2001. 96(6): p. 1791-6., https://pubmed.ncbi.nlm.nih.gov/11419831/
672. Didden, P., Reijm, A. N., Erler, N. S., Wolters, L. M. M., Tang, T. J., Ter Borg, P. C. J., et.al. Fully vs. partially covered selfexpandable metal stent for palliation of malignant esophageal strictures: a randomized trial (the COPAC study), Endoscopy, 2018. 50(10): p. 961-971., https://www.ncbi.nlm.nih.gov/pubmed/29895072
673. Wang, C, Wei, H, Li, Y, Comparison of fully-covered vs partially covered self-expanding metallic stents for palliative treatment of inoperable esophageal malignancy: a systematic review and meta-analysis., BMC Cancer, 2020. 20 (1)(1): p. 73., https://pubmed.ncbi.nlm.nih.gov/32000719/
674. Miyayama, S., Matsui, O., Kadoya, M., Yoshikawa, J., Gabata, T., Kitagawa, K., et.al. Malignant esophageal stricture and fistula: palliative treatment with polyurethane-covered Gianturco stent, J Vasc Interv Radiol, 1995. 6(2): p. 243-8., https://pubmed.ncbi.nlm.nih.gov/7540443/
675. Alexander, E. P., Trachiotis, G. D., Lipman, T. O., Wadleigh, R. G., Evolving management and outcome of esophageal cancer with airway involvement, Ann Thorac Surg, 2001. 71(5): p. 1640-4., https://pubmed.ncbi.nlm.nih.gov/11383814/
676. Conio, M., Repici, A., Battaglia, G., De Pretis, G., Ghezzo, L., Bittinger, M., et.al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia, Am J Gastroenterol, 2007. 102(12): p. 2667-77., https://pubmed.ncbi.nlm.nih.gov/18042102/
677. Pandit, S., Samant, H., Morris, J., Alexander, S. J., Efficacy and safety of standard and anti-reflux self-expanding metal stent: A systematic review and meta-analysis of randomized controlled trials, World J Gastrointest Endosc, 2019. 11(4): p. 271-280., https://www.ncbi.nlm.nih.gov/pubmed/31040888
678. Dua, KS, DeWitt, JM, Kessler, WR, Diehl, DL, Draganov, PV, Wagh, MS, et.al. A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video)., Gastrointest Endosc, 2019. 90 (1)(1): p. 64-74.e3., https://pubmed.ncbi.nlm.nih.gov/30684601/
679. Yang, ZM, Geng, HT, Wu, H, Radioactive Stent for Malignant Esophageal Obstruction: A Meta-Analysis of Randomized Controlled Trials., J Laparoendosc Adv Surg Tech A, 2021. 31 (7)(7): p. 783-789., https://pubmed.ncbi.nlm.nih.gov/32915105/
680. Lu, Y. F., Chung, C. S., Liu, C. Y., Shueng, P. W., Wu, L. J., Hsu, C. X., et.al. Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not?, Oncologist, 2018. 23(12): p. 1426-1435., https://www.ncbi.nlm.nih.gov/pubmed/29728468
681. Ribeiro, M. S. I., da Costa Martins, B., Simas de Lima, M., Franco, M. C., Safatle-Ribeiro, A. V., de Sousa Medeiros, V., et.al. Self-expandable metal stent for malignant esophagorespiratory fistula: predictive factors associated with clinical failure, Gastrointest Endosc, 2018. 87(2): p. 390-396., https://www.ncbi.nlm.nih.gov/pubmed/28964748
682. Adamson, D, Byrne, A, Porter, C, Blazeby, J, Griffiths, G, Nelson, A, et.al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial., Lancet Gastroenterol Hepatol, 2021. 6 (4)(4): p. 292-303., https://pubmed.ncbi.nlm.nih.gov/33610215/
683. Xu, Z, Liu, H, Li, S, Han, Z, Chen, J, Liu, X, et.al. Palliative radiotherapy combined with stent insertion to relieve dysphagia in advanced esophageal carcinoma patients: A systematic review and meta-analysis., Front Oncol, 2022. 12 (): p. 986828., https://pubmed.ncbi.nlm.nih.gov/36172146/
684. Bergquist, H., Wenger, U., Johnsson, E., Nyman, J., Ejnell, H., Hammerlid, E., et.al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial, Dis.Esophagus., 2005. 18(3): p. 131-139., https://pubmed.ncbi.nlm.nih.gov/16045572/
685. Wenger, U., Johnsson, E., Arnelo, U., Lundell, L., Lagergren, J., An antireflux stent versus conventional stents for palliation of distal esophageal or cardia cancer: a randomized clinical study, Surg.Endosc., 2006. 20(11): p. 1675-1680., https://pubmed.ncbi.nlm.nih.gov/16960663/
686. Bergquist, H., Johnsson, E., Nyman, J., Rylander, H., Hammerlid, E., Friesland, S., et.al. Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer--results of a prospective safety study, Dis Esophagus, 2012. 25(5): p. 410-5., https://pubmed.ncbi.nlm.nih.gov/21899654/
687. Carazzone, A., Bonavina, L., Segalin, A., Ceriani, C., Peracchia, A., Endoscopic palliation of oesophageal cancer: results of a prospective comparison of Nd:YAG laser and ethanol injection, Eur J Surg, 1999. 165(4): p. 351-6., https://pubmed.ncbi.nlm.nih.gov/10365837/
688. Spencer, G. M., Thorpe, S. M., Blackman, G. M., Solano, J., Tobias, J. S., Lovat, L. B., et.al. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study, Gut, 2002. 50(2): p. 224-7., https://pubmed.ncbi.nlm.nih.gov/11788564/
689. Norberto, L., Ranzato, R., Marino, S., Angriman, I., Erroi, F., Donadi, M., et.al. Endoscopic palliation of esophageal and cardial cancer: neodymium-yttrium aluminum garnet laser therapy, Dis Esophagus, 1999. 12(4): p. 294-6., https://pubmed.ncbi.nlm.nih.gov/10770365/
690. Loizou, L. A., Grigg, D., Atkinson, M., Robertson, C., Bown, S. G., A prospective comparison of laser therapy and intubation in endoscopic palliation for malignant dysphagia, Gastroenterology, 1991. 100(5 Pt 1): p. 1303-10., https://pubmed.ncbi.nlm.nih.gov/1707386/
691. Carter, R., Smith, J. S., Anderson, J. R., Laser recanalization versus endoscopic intubation in the palliation of malignant dysphagia: a randomized prospective study, Br J Surg, 1992. 79(11): p. 1167-70., https://pubmed.ncbi.nlm.nih.gov/1281732/
692. Barr, H., Krasner, N., Raouf, A., Walker, R. J., Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia, Gut, 1990. 31(3): p. 252-8., https://pubmed.ncbi.nlm.nih.gov/1691125/
693. Manner, H., May, A., Faerber, M., Pech, O., Plum, N., Ell, C., The tissue effect of second generation argon plasma coagulation (VIO APC) in comparison to standard APC and Nd:YAG laser in vitro, Acta Gastroenterol Belg, 2007. 70(4): p. 352-6., https://pubmed.ncbi.nlm.nih.gov/18330091/
694. Eickhoff, A., Jakobs, R., Schilling, D., Hartmann, D., Weickert, U., Enderle, M. D., et.al. Prospective nonrandomized comparison of two modes of argon beamer (APC) tumor desobstruction: effectiveness of the new pulsed APC versus forced APC, Endoscopy, 2007. 39(7): p. 637-42., https://pubmed.ncbi.nlm.nih.gov/17611919/
695. Manner, H., May, A., Rabenstein, T., Pech, O., Nachbar, L., Enderle, M. D., et.al. Prospective evaluation of a new high-power argon plasma coagulation system (hp-APC) in therapeutic gastrointestinal endoscopy, Scand J Gastroenterol, 2007. 42(3): p. 397-405., https://pubmed.ncbi.nlm.nih.gov/17354121/
696. Hanada, Y, Leggett, CL, Iyer, PG, Linn, B, Mangels-Dick, T, Wang, KK, Spray cryotherapy prevents need for palliative stenting in patients with esophageal cancer-associated dysphagia., Dis Esophagus, 2022. 35 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/34318325/
697. Kachaamy, T, Prakash, R, Kundranda, M, Batish, R, Weber, J, Hendrickson, S, et.al. Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer., Gastrointest Endosc, 2018. 88 (3)(3): p. 447-455., https://pubmed.ncbi.nlm.nih.gov/29750984/
698. Rupinski, M., Zagorowicz, E., Regula, J., Fijuth, J., Kraszewska, E., Polkowski, M., et.al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II), The American.journal of gastroenterology, 2011. 9:, https://pubmed.ncbi.nlm.nih.gov/21670770/
699. Dempster, M., McCorry, N. K., Brennan, E., Donnelly, M., Murray, L., Johnston, B. T., Psychological distress among survivors of esophageal cancer: the role of illness cognitions and coping, Dis Esophagus, 2012. 25(3): p. 222-7., https://pubmed.ncbi.nlm.nih.gov/21819485/
700. Djärv, Therese, Lagergren, Pernilla, Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery, European journal of cancer, 2011. 47(4): p. 530-535., https://pubmed.ncbi.nlm.nih.gov/21074989/
701. Heijl, Mark, Sprangers, MirjamA G., Boer, AngelaG E. M., Lagarde, SjoerdM, Reitsma, HansB, Busch, OlivierR C., et.al. Preoperative and Early Postoperative Quality of Life Predict Survival in Potentially Curable Patients with Esophageal Cancer, Annals of Surgical Oncology, 2010. 17(1): p. 23-30., https://pubmed.ncbi.nlm.nih.gov/19830496/
702. Gockel, I., Gönner, U., Domeyer, M., Lang, H., Junginger, Th, Long-term survivors of esophageal cancer: Disease-specific quality of life, general health and complications, Journal of Surgical Oncology, 2010. 102(5): p. 516-522., https://pubmed.ncbi.nlm.nih.gov/19877161/
703. National Comprehensive Cancer Network. Distress Management. NCCN Clinical Practice Guidelines in Oncology. 2011
704. Herschbach P, Weis J, Screeningverfahren in der Psychoonkologie.Testinstrumente zur Identifikation betreuungsbeduerftiger Krebspatienten, Dt. Krebsgesellschaft, 2010. p. http://www.krebsgesellschaft.de/download/pso_broschuere.pdf., https://www.wpo-ev.de/wp-content/uploads/2023/07/Screening_broschuere.pdf
705. Mehnert, A., Lehmann, C., Cao, P., Koch, U., [Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56(12): p. 462-79., https://pubmed.ncbi.nlm.nih.gov/17160791/
706. Mitchell, A. J., Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis, J Natl Compr Canc Netw, 2010. 8(4): p. 487-94., https://pubmed.ncbi.nlm.nih.gov/20410338/
707. Vodermaier, A., Linden, W., Siu, C., Screening for emotional distress in cancer patients: a systematic review of assessment instruments, J Natl Cancer Inst, 2009. 101(21): p. 1464-88., https://pubmed.ncbi.nlm.nih.gov/19826136/
708. Vodermaier, A., Millman, R. D., Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis, Support Care Cancer, 2011. 19(12): p. 1899-908., https://pubmed.ncbi.nlm.nih.gov/21898134/
709. Weis, J., Schumacher, A., Blettner, G., Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin, Der Onkologe, 2007. 13: p. 185-194., https://www.researchgate.net/publication/262829754_Psychoonkologie_Konzepte_und_Aufgaben_einer_jungen_Fachdisziplin
710. Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Kuffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis, J Clin Oncol, 2013. 31(6): p. 782-93., https://pubmed.ncbi.nlm.nih.gov/23319686/
711. Hamano, J, Morita, T, Inoue, S, Ikenaga, M, Matsumoto, Y, Sekine, R, et.al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study., Oncologist, 2015. 20 (7)(7): p. 839-44., https://pubmed.ncbi.nlm.nih.gov/26054631/
712. Moroni, M, Zocchi, D, Bolognesi, D, Abernethy, A, Rondelli, R, Savorani, G, et.al. The 'surprise' question in advanced cancer patients: A prospective study among general practitioners., Palliat Med, 2014. 28 (7)(7): p. 959-964., https://pubmed.ncbi.nlm.nih.gov/24662237/
713. Murray, S, Boyd, K, Using the 'surprise question' can identify people with advanced heart failure and COPD who would benefit from a palliative care approach., Palliat Med, 2011. 25 (4)(4): p. 382., https://pubmed.ncbi.nlm.nih.gov/21610113/
714. Moss, AH, Lunney, JR, Culp, S, Auber, M, Kurian, S, Rogers, J, et.al. Prognostic significance of the "surprise" question in cancer patients., J Palliat Med, 2010. 13 (7)(7): p. 837-40., https://pubmed.ncbi.nlm.nih.gov/20636154/
715. Schuler, Ulrich S., Hornemann, Beate, Hoffnung und „double awareness“ in der palliativen Onkologie, 2020. 35(3): p. 219 - 222., https://doi.org/10.1007/s12312-020-00782-3
716. Chen, CH, Kuo, SC, Tang, ST, Current status of accurate prognostic awareness in advanced/terminally ill cancer patients: Systematic review and meta-regression analysis., Palliat Med, 2017. 31 (5)(5): p. 406-418., https://pubmed.ncbi.nlm.nih.gov/27492160/
717. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Manual Qualitätsindikatorenäzq Schriftenreihe, 2009. 36:, http://www.aezq.de/aezq/publikationen/schriftenreihe
718. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 3.0., 2021., https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik/
719. Vlayen Joan, De Gendt Cindy, Stordeur Sabine, Schillemans Viki, Camberlin Cécile, Vrijens France, et.al. Quality indicators for the management of upper gastrointestinal cancer, 2013., https://kce.fgov.be/publication/report/quality-indicators-for-the-management-of-upper-gastrointestinal-cancer#.VRpuXeHbw20
720. Walters, D. M., McMurry, T. L., Isbell, J. M., Stukenborg, G. J., Kozower, B. D., Understanding mortality as a quality indicator after esophagectomy, Ann Thorac Surg, 2014. 98(2): p. 506-11; discussion 511-2., https://pubmed.ncbi.nlm.nih.gov/24841544/
721. Talsma, A. K., Lingsma, H. F., Steyerberg, E. W., Wijnhoven, B. P., Van Lanschot, J. J., The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care, Ann Surg, 2014. 260(2): p. 267-73., https://pubmed.ncbi.nlm.nih.gov/25350650/